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Abstract 
Prevalence of Aspirin Receipt and Discontinuation Amongst Veterans Health 
Administration Community Living Center Residents with Indications for Secondary 
Prevention of Cardiovascular Events 
Sydney Patricia Springer, PharmD 
 
University of Pittsburgh, 2019 
 
 
 
 
Background: Continuation of aspirin for secondary prevention (ASP) in patients with 
limited life expectancy and/or advanced dementia (LLE/AD) is controversial, given increased risks 
and unclear evidence about continued benefits; yet little is known about patterns of use of ASP in 
this population. This study aimed to 1) describe prevalence and predictors of ASP amongst 
Veterans at admission to Veterans Affairs (VA) Community Living Centers (CLCs) and 2) assess 
cumulative incidence and factors predicting aspirin discontinuation within 90 days after admission 
to a VA CLC.  
Methods: We performed a retrospective cohort study in Veterans with LLE/AD admitted 
to a VA CLC for ≥7 days in fiscal years 2009-15, who had history of coronary artery disease and/or 
stroke. ASP was defined as receipt of a preventive dose (25-325 mg daily) on ≥1 day in the first 7 
days of the stay. Resident, caregiver, and facility level characteristics were extracted from 
admission Minimum Dataset (MDS) assessments, VA Corporate Data Warehouse, and Medicare 
claims. Multivariable logistic regression was used to determine factors associated with ASP at 
CLC admission.  Fine and Gray subdistribution hazard models with death as a competing risk were 
used to identify predictors of aspirin discontinuation.  
Results: The sample (n=37,165 CLC episodes) was 98% male, 78% white, and 35% aged 
 85 year; 48% received aspirin in the first week of the CLC stay. The strongest predictor of higher 
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odds of ASP was having a myocardial infarct in the last year (aOR=1.99, 95% CI=1.79-2.22). A 
total of 13,844 episodes qualified for the discontinuation analysis; cumulative incidence of ASP 
discontinuation was 33% by day 91 of the CLC stay. Strong predictors of aspirin discontinuation 
were documentation of limited prognosis or hospice use (aSDHR 1.90, 95% CI 1.67-2.14) and 
greater ADL dependency. 
Conclusion: Just under half of older adults with LLE/AD used ASP at CLC admission, 
and a third of those discontinued ASP in the first 91 days. Wide variability in aspirin prescribing 
may reflect the unclear role of aspirin in end-of-life amongst prescribers. Given the controversy of 
continuing ASP at end-of-life, future research should assess outcomes of ASP discontinuation in 
this population.   
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1.0 Introduction 
 
1.1 Burden of Cardiovascular Disease 
It is estimated that over 92 million American adults have a diagnosis of cardiovascular 
disease (CVD), and CVD is the number one cause of death globally and in the United States 
(U.S).1, 2 CVD consists of a constellation of diagnoses, including cerebrovascular disease and 
coronary artery disease (CAD).2 An estimated $200 billion is spent on heart disease alone annually 
in the U.S.1 
 
1.2 Recommendations for Initiation of Aspirin to Reduce Cardiovascular Events 
A major focus in reducing morbidity and mortality related to CVD is on the prevention of 
secondary cardiovascular events. Aspirin is a first-line agent for the prevention of a secondary 
CVD event, including stroke, transient ischemic attack (TIA), and myocardial infarction, although 
the percentage of people with CVD who are actually prescribed aspirin ranges from 57-71%.3-6 A 
number of guidelines strongly recommend aspirin for secondary prevention in those with or 
without diabetes and a history of CVD when the perceived benefit outweighs potential risk.7, 8 The 
American Heart Association (AHA) and the American Stroke Association recommend aspirin at 
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doses of 50-325 mg daily, over warfarin, in patients with a history of stroke or TIA (Grade IB 
recommendation), and for patients unable to take anticoagulation in those with paroxysmal or 
permanent atrial fibrillation (Grade IA).4 Aspirin combined with extended-release dipyridamole is 
also recommended in those with a history of stroke or TIA and cardiomyopathy (Grade IIB).4 The 
American College of Chest Physicians recommends aspirin in those with a history of non-
cardioembolic stroke or TIA at doses of 75-100 mg daily or aspirin combined with extended 
release dipyridamole (Grade 1A), and aspirin in those with a history of ischemic stroke or TIA and 
atrial fibrillation (Grade IB).6 The AHA and the American College of Cardiology Foundation 
(ACCF) recommend aspirin at doses of 75-162 mg daily for patients with coronary artery disease 
(CAD) (Grade IA), daily doses of 100-325 mg daily for 1 year after undergoing coronary artery 
bypass grafting (CABG) (Grade IA), 75-325 mg of aspirin daily for those with a history of stroke 
or TIA or in combination with extended release dipyridamole twice daily (Grade IA), and aspirin 
81 mg daily after a percutaneous intervention (Grade IB).5 Only the AHA/ASA and the Chest 
guidelines recommend individualizing antiplatelet choices, with the Chest physicians only 
recommending against aspirin in the setting of weak evidence and high bleeding risk – noting lack 
of validated tools for bleed risk assessment outside of atrial fibrillation.4, 6 Overall, current 
guidelines report strong evidence to initiate and continue aspirin in the setting of secondary CVD 
prevention, and avoid recommendations addressing the optimal duration of use, except in the 
context of after a CABG. 
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1.3 Benefits of Aspirin for Secondary Prevention 
The evidence supporting aspirin’s benefit in the secondary prevention of CVD events is 
fairly clear in the short-term.9-12 Aspirin administered shortly after an ischemic stroke or a coronary 
revascularization is associated with reduced mortality, better functional outcomes and reduced 
recurrence of stroke or myocardial infarction in studies following patients for 4-24 weeks after an 
ischemic stroke.6, 13 A meta-analysis of randomized controlled trials of aspirin for the secondary 
prevention of CVD showed reduced risk of major coronary events (non-fatal myocardial 
infarctions, coronary heart disease mortality), stroke (ischemic and stroke due to unknown cause), 
vascular death, and any serious vascular events by about 20% compared to those not receiving 
aspirin.14 Additionally, studies have reported a prothrombotic state shortly after aspirin 
discontinuation15, which has been supported by a number of case-reports (n=2-13 patients), and 
several retrospective and case-control studies.16-20 This prothrombotic window appears to range 
from 8-25 days, in which patients are at highest risk of subsequent CVD events after aspirin 
discontinuation.21 While case-reports offer low-quality evidence to support this risk after aspirin 
discontinuation, one meta-analysis included 2 retrospective studies assessing aspirin receipt prior 
to myocardial infarctions or acute coronary syndromes, and found that 2.3-10.2% of these patients 
had recently discontinued aspirin (mean duration of aspirin use prior to event was about 4 years).21 
The combination of strong evidence to prescribe aspirin upon a CVD event, and risk of a potential 
prothrombotic state upon discontinuation, likely contributes to the continued use of aspirin in the 
long-term for many patients, despite a lack of direct evidence to support long-term benefit beyond 
5 years.22   
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The benefit-to-risk ratio of long-term aspirin use is not as clear, especially in older adults.14, 
22, 23 Most studies providing evidence for reduced cardiovascular and cerebrovascular events as a 
result of use of aspirin for secondary CVD prevention had a short duration of follow-up, only 
following patients for a mean duration of 3 weeks to 29 months23 and lack evidence to support 
long-term benefit in older adults beyond 5 years.22 Thus, it is unclear if the benefit from aspirin 
for secondary prevention continues beyond the duration of these trials and justifies the continued 
use of aspirin as patients age and approach the end-of-life. 
1.4 Risks of Aspirin for Secondary Prevention 
In addition to questions regarding continued benefit as adults age, a major consideration 
for continued aspirin use includes the risks of bleeding events. In a systematic review of 16 studies 
(N=17,000) assessing risk of bleeding in adults on aspirin for secondary prevention, the risk of 
extracranial bleeding was actually higher than in those on aspirin for primary prevention. There 
was an almost 3-fold risk of major extracranial bleeding (RR 2.69, 95% CI 1.25-5.76) in secondary 
prevention trials, and a 1.5-fold increased risk of bleeding in primary prevention studies (RR 1.54, 
95% CI 1.30-1.82). Hemorrhagic strokes were elevated in those on aspirin for secondary 
prevention, though this was not statically significant (RR 1.67, 95% CI 0.97-2.90). Importantly, 
hemorrhagic strokes are considered more dangerous than ischemic strokes, especially in older 
adults.14 In a population-based cohort study, amongst 3,166 aspirin-user on therapy for secondary 
prevention, risk of major bleeding was associated with increased age, especially amongst fatal 
bleeds (HR 5.53, 95% CI 2.65-11.54). Additionally, those 75 years of age and older were at higher 
risk for major upper gastrointestinal bleeding (HR 4.13, 95% CI 2.60-6.57), and fatal or disabling 
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gastrointestinal bleeding (HR 10.26, 95% CI 4.37-24.13).24 Despite the bleeding risk, guidelines 
do not explicitly indicate what to do in those who are already at high risk of a bleeding event, such 
as older adults, except to consider individualizing therapy if the evidence to support use is weak.6  
 
1.5 Potential for Increased Risks of Aspirin for Secondary Prevention in Older Adults with 
Limited Life Expectancy 
The risk-to-benefit ratio is even more complicated by the physiological changes that affect 
the pharmacokinetics and pharmacodynamics of medications in older adults.25 These physiological 
changes, such as decreased metabolism, elimination, hepatic blood flow, increased body fat, and 
reduced lean muscle mass and total body water, place older adults at a higher risk of adverse drug 
reactions due to higher bioavailability at typical adult medication doses and reduced first pass 
metabolism.25 When patients are co-prescribed aspirin with warfarin, for example, they are at a 
higher risk of bleeding events than their younger counterparts due to a reduction in cytochrome 
P450 metabolizing enzyme activity with age.25, 26 Pharmacokinetic changes could contribute to 
higher bioavailability of aspirin, which is metabolized to an inactive component in the gastric 
mucosa and in liver.27  Slower gastric emptying time in older adults could partially explain the 
higher risk of gastrointestinal bleeding amongst older adults.28 Additionally, as patients near the 
end-of-life (EOL), there are major physiological changes which occur that can increase the risk of 
adverse drug reactions, such as reduced gastric motility, delayed gastric emptying, decreased 
hepatic blood flow, and fluid deficits – all of which can increase the bioavailability of aspirin. The 
adverse events can occur even if they have been on that drug for a long period of time.29-31 
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Two notable trials of aspirin were also published recently, which suggest decreased CVD 
benefits and increased bleeding risk associated with aspirin use in older adults. The ASPirin in 
Reducing Events in the Elderly (ASPREE) trial was a RCT of 19,114 community-dwelling older 
adults who did not have cardiovascular disease. The researchers found no significant benefit in 
reducing cardiovascular disease and an increased risk of major hemorrhage.32 The ASCEND (A 
Study of Cardiovascular Events in Diabetes) study group found a benefit of reducing 
cardiovascular events in a cohort of older adults with diabetes and no prior cardiovascular disease, 
but an excess risk of major bleeding.33  Such a long-term study of aspirin for secondary prevention 
has not been conducted, though these two studies will likely prompt the re-assessment of aspirin 
use in older adults generally, as aspirin had previously been considered a safe and effective agent 
for primary prevention in this population.  
  
1.6 Potential for Lack of Continued Benefit in Older Adults with Limited Life Expectancy 
 
In older adults with limited life expectancy, another consideration as to whether aspirin should be 
used for secondary prevention is the expected time to benefit in relation to the patient’s remaining 
estimated life expectancy. The time to benefit (TTB) for a medication can often only be ascertained 
by randomized clinical trials (RCTs)– using the time at which a statistically significant difference 
is seen between those on the medication and those on the control. Going one step further, the effect 
size at this TTB should be considered as well by using number needed to treat (NNT) compared 
to the number needed to harm (NNH) in an effort to weigh the benefits and risks. In those with a 
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limited life expectancy (LLE), the TTB of a new agent may exceed the patient’s estimated life 
expectancy, putting into question whether or not a patient will realize the full benefit of the 
medication. Alternatively, patients who are on a medication for a long period of time often surpass 
the TTB of a medication that was determined in the RCT. Often the TTB is shorter, or as long, in 
duration as the clinical trial, which is a major limitation given that many medications, especially 
those for chronic conditions, are taken for life.34   
1.7 Rationale for Considering the Discontinuation of Aspirin for Secondary Prevention in 
Older Adults with Limited Life Expectancy 
Because of these physiological changes and potential changes in the benefit-to-risk ratio, 
the time when the provider becomes aware that a patient has LLE poses an excellent time to 
consider evaluating the utility, including TTB and TTH, of all medications the patient is taking. 34 
Holmes and colleagues suggested a framework for prescribing medications at end of life, in which 
she notes the number of appropriate medications is reduced as the goal of care moves from curative 
to palliative, and life expectancy reduces.35 Holmes recommends optimizing prescribing at EOL 
by focusing on medications which reduce burden, avoid harms, and improve quality of life, while 
reducing or deprescribing medications and focusing on the goals of care of the older adult with 
LLE, which often shift from curative/preventive to palliative.29 In a setting where the goal is 
palliative versus curative or preventive, several medications are expected to be initiated to alleviate 
symptoms, thus it is important to consider discontinuing medications with increased short-term 
risks and/or reduced benefits, to reduce pill burden.29  
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Unfortunately, there is almost no literature to directly support or refute the safety of 
discontinuing aspirin in patients near the EOL, and very few studies which assess patterns of use 
of aspirin or antiplatelet therapy at EOL.36 A recent systematic review found that while 10 RCTs, 
2 case-control studies and 7 cohort studies assessed the discontinuation of preventive medications 
at EOL, only one of these studies assessed the discontinuation of aspirin specifically.37  The study 
consisted of a small observational study (n=60) assessing medication discontinuation in the last 
months of life (n=60).  The outcomes of aspirin discontinuation in this patient was not reported.38  
 
The absence of data on outcomes of aspirin discontinuation in older adults with limited life 
expectancy likely explains the lack of guidance in CVD treatment guidelines and other geriatric 
prescribing guidelines, regarding the optimal duration of aspirin therapy and whether it should be 
discontinued in patients approaching the EOL. For example, the STOPPFrail criteria were recently 
published and specified that all anti-platelets for the indication of primary prevention should be 
considered for deprescribing in the LLE setting. This consensus group rejected the criteria to 
include anticoagulation, noting that while the risk of bleeding was high, in a minority of patients 
discontinuing anticoagulation may be inappropriate. While many agreed that anticoagulation 
should likely be discontinued at EOL, the lack of evidence describing the risk of deprescribing or 
discontinuing these agents prevented them from recommending it.36 In addition, Holmes and 
colleagues assessed the feasibility of creating a deprescribing consensus guideline for palliative 
care patients with advanced dementia. Twelve geriatricians who were board certified in Palliative 
Medicine were involved in a modified Delphi consensus panel, where 34 resident medication lists 
were reviewed. Of the 81 medications included, consensus was reached on 69 of these medications 
(always appropriate, sometimes appropriate, rarely appropriate, or never appropriate). Aspirin was 
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one of 12 medications in which no consensus was reached regarding whether or not it should be 
continued in this population.35 The authors noted a need for future research to assess the effects of 
aspirin discontinuation in patients with advanced dementia, especially considering its widespread 
use in this population.  
 
1.8 Lack of Evidence Regarding Continued Use of Aspirin Near EOL Likely Contributes to 
Treatment Variation 
Despite a lack of research evaluating the outcomes of aspirin discontinuation in older adults 
with LLE, a survey of 134 physicians who were given clinical vignettes of an older adult with 
CVD and progressively worsening cognitive function and dependency found that aspirin in the 
context of secondary prevention was the most common medication recommended for 
discontinuation.39 Across all medications, the most common reason for deprescribing medications 
was dementia severity and pill burden. They also found that older physicians were less likely than 
younger physicians to rank LLE and cognitive impairment as important in considering 
deprescribing, and trainees were more likely to discontinue medications for secondary 
prevention.39 Given this survey came after the assessment by Holmes, it is possible that 
discontinuation of aspirin is becoming less controversial in practice. However, the unclear risk-to-
benefit ratio for continuation of aspirin in EOL, and lack of clinical consensus of best practices 
around aspirin prescribing near EOL, likely contribute to ambiguity for prescribers and the need 
to better understand prescribing practices amongst those with LLE.  
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There have been a handful of studies examining patterns of aspirin use and discontinuation 
in patients near the EOL. In one study of chronic medication use in the weeks just prior to death, 
one-third of patients remained on aspirin one week prior to their death.40 In a study of patients 
discharged to hospice care, over 57% remained on aspirin, 26% remained on the anticoagulant 
enoxaparin, and 21% remained on warfarin; furthermore, 22% of these patients were newly 
initiated on these medications prior to hospice admission.41 Common amongst these studies was 
the lack of reporting of additional factors which can often increase or decrease the odds of 
prescribing or discontinuing aspirin, including facility level factors of the nursing home or hospice 
care unit they are discharge to, comorbid cardiovascular risk factors, or information regarding next 
of kin (NOK). Additionally, these were fairly small, single-site hospice studies, limiting 
generalizability to the broader nursing home population at EOL, not explicitly on hospice care. 
Thus, further research on rates of aspirin use and discontinuation in large, generalizable samples 
of older adults near the end of life are needed, along with studies examining the impact of aspirin 
discontinuation on CV events and other patient-centered outcomes. 
 
The VHA CLC is a nursing home setting, which providers Veterans with rehabilitation, 
skilled nursing care, assisted living, respite, hospice and other care for older or previously 
hospitalized Veterans. The VHA CLC population provides a unique opportunity to study aspirin 
prescribing patterns in patients near the EOL because of the availability of daily medication records 
for capturing detailed information on daily aspirin use and the ability to link these data to 
information on resident prognosis and health status, as well as facility characteristics that may 
affect discontinuation. In non-VHA claims data it can be increasingly difficult to assess aspirin 
use, given that the medication is available over the counter (OTC) and often not prescribed. Even 
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in non-VHA nursing home settings it is not uncommon for residents to bring in their own OTC 
agents, including aspirin. Thus, this setting provided the ideal dataset for assessing prescribing and 
discontinuation patterns in patients with LLE and AD, which could be generalizable to older adults 
at EOL. We included patients with AD, because the mortality risks have been estimated at over 
50% over 6-18 months16, 42, consistent with other terminal diseases.43  
 
1.9 Objectives 
The first aim of this study is to describe prevalence of and factors associated with aspirin 
receipt for secondary prevention of cardiovascular disease (those with a history of CAD and/or 
TIA/stroke) at the time of CLC admission. The second aim of this study is to assess, among CLC 
residents who received aspirin for secondary prevention at admission, the cumulative incidence of 
subsequent aspirin discontinuation during the first 90 days after CLC admission and identify 
resident and facility characteristics associated with discontinuation. 
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2.0 _Methods 
 
A retrospective cohort study was conducted using administrative and clinical data collected from 
the Veterans Health Administration (VHA) from fiscal years (FY) 2009-2015. The Veterans 
Affairs Pittsburgh Healthcare System’s Institutional Review Board approved this study. 
2.1 Conceptual Model 
To guide our investigation, we developed a conceptual model of factors which may 
influence prescribing and discontinuation of aspirin in nursing home residents with LLE/AD, 
based on a literature review. The model included the following factors: socio-demographics, 
environment of care, cardiovascular risk factors, markers of poor prognosis, facility characteristics, 
and bleeding risk factors. See Figure 1 below for the complete model.  
 
Socio-demographics. Socio-demographics, including age, race/ethnicity, and sex, are 
included based on a study by Zullo and colleagues which found that the initiation of medications 
for secondary CVD prevention (i.e., beta-blockers and statins) in older adults admitted to a nursing 
home after a myocardial infarction (MI) was less likely in adults aged 85 years or older, as well as 
females.44 In a study assessing receipt of anti-platelets or anticoagulant therapy in those with a 
history of stroke, the researchers found similar results and also noted a racial disparity, with lower 
odds of prescribing amongst Black compared to White patients.45 Racial, ethnic and sex-based 
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disparities have also been reported in a systematic review of studies assessing the frequency of 
differences in these variables in medication treatment; they found that 73% of studies demonstrated 
disparities related to receipt of a evidence-based medication for chronic diseases.46  
 
Environment of Care Factors. Several contextual factors surrounding the nursing home 
admission may also influence whether the resident is admitted on aspirin or is discontinued going 
forward. For example, residents admitted in more recent years may be more likely to have already 
been deprescribed aspirin or may discontinue aspirin after admission, as attention to deprescribing 
has gained traction in the literature. In addition, as medications are often initiated or restarted in 
the hospital setting, residents who are admitted from hospital rather than community settings or 
who were recently hospitalized may be more likely to enter the nursing home taking aspirin.44, 47 
In addition, the involvement of a caregiver may influence the prescribing of aspirin, as often in 
older adults with LLE or AD, the NOK and/or caregivers are responsible for healthcare related 
decision making. Pruskowski and colleagues surveyed conference attendees during The Society 
for Post-Acute and Long-Term Care Medicine Annual Conference, and found that deprescribing 
was more likely when either the patient, or their family/caregiver, indicate the deprescribing would 
improve quality of life.48 While quality of life is difficult to assess in administration data, assessing 
who is listed as the NOK, their relationship to the Veteran, and their geographic distance to the 
CLC, could be important to whether a patient is continued on or discontinued from their chronic 
medications.  
 
Cardiovascular Risk Factors. Specific risk factors for cardiovascular events may reduce 
the prescriber’s propensity to consider discontinuation of aspirin, an idea which is supported by 
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several previous studies. In one study, recent hospitalization for a stroke resulted in significant 
changes to the odds of receipt of preventive CV medications – reducing the effect size of factors 
that were previously associated with higher odds of prescribing (such as atrial fibrillation, 
hypertension, CAD, peripheral vascular disease).45 Risk factors for CVD have also been shown to 
be implicated in prescribing of chronic medications for secondary prevention, with higher odds of 
prescribing amongst those with CHF and recent coronary revascularization or angioplasty; lower 
odds of prescribing occurred in those with atrial fibrillation, and stable and unstable angina.44 
These studies also found that a history of stroke, atrial fibrillation, hypertension, CAD, and 
peripheral vascular disease predicted higher odds of prescribing.44, 45  
 
Markers of Poor Prognosis. It is possible that when residents present with specific markers 
of poor prognosis (e.g., cancer, poor appetite, dehydration, advanced dementia) or signs and 
symptoms that may make taking medications more difficult (e.g., intravenous (IV) feeding tube 
placement, swallowing problems), prescribers may be prompted to review the medication list and 
discontinue those that are least likely to benefit or most likely to harm a patient. In the previous 
studies examining the use of chronic medications for secondary CV prevention, use of these 
medications was less likely in those with an Alzheimer’s disease diagnosis, moderate to severe 
cognitive impairment compared to those with no cognitive impairment, and in those with more 
extensive dependence in ADLs.44, 45  
 
Facility Characteristics. A survey of Vancouver family physicians found that common 
barriers to deprescribing include organizational factors, poor records in nursing home facilities, 
and lack of training of staff on the role of deprescribing, suggesting that facility level factors may 
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impact whether or not a patient is deprescribed or discontinued from their aspirin.49 As such, 
specific factors such as region of the country44, rural/urban location, bed size, complexity (i.e., 
academic affiliation and range of specialty services offered)) of the VHA parent station with which 
the CLC is affiliated, and staff turnover rates could contribute to the environment of a patient’s 
care, but have yet to be fully explored in this population. 
 
Bleeding Risk Factors. There is significant literature which supports the premise that 
proton pump inhibitors reduce the incidence of gastrointestinal bleeding in those on aspirin 
therapy24, and some data supporting similar protection with H2 receptor antagonists (H2RAs).50 
Concomitant use of aspirin with medications such as non-steroidal anti-inflammatory drugs 
(NSAIDs), cyclooxygenase-2 (COX2) inhibitors, anti-platelets and anti-coagulants has also been 
associated with increased risk of bleeding, and these interactions are guidelines for appropriate 
prescribing in older adults (Beers Criteria, 2015, 2019). Thus, use of these medications may be 
potential predictors of aspirin use and discontinuation in this study.   
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Aspirin 
Receipt
Bleeding Risk 
Factors
Socio-
Demographic
Environment of 
Care
Cardiovascular 
Risk Factors
Markers of Poor 
prognosis
Facility Level 
Factors
Medications related to reduced or increased bleeding risk: anticoagulants, antiplatelets, non-steroidal anti-
inflammatory drugs (NSAIDs), proton pump inhibitors, H2 receptor antagonists 
Sex, age, race, ethnicity, 
marital status 
Fiscal year of admission, 
living arrangements before 
admission, recent 
hospitalization, next-of-kin 
information 
Region of CLC, rurality, complexity 
level of CLC facility, bed size, staff 
turnover rates 
Coronary artery disease, stroke, transient ischemic attack, diabetes, congestive heart 
failure, hypertension, hyperlipidemia, recent venous thromboembolism, atrial fibrillation, 
recent myocardial infarction, history of smoking, body mass index 
Advanced dementia, number of 
chronic comorbidities, weight 
loss, poor appetite, renal 
failure, dehydration, acute 
changes in mental status, 
shortness of breath, cancer, 
higher dependency on activities 
of daily living, behavioral 
problems, requirement of 
intravenous feeding tubes, 
presence of pain, history of 
falls or fractures 
Figure 1: Conceptual Model for Aspirin Receipt 
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2.2 Data Sources 
Data for this study was obtained from several administrative healthcare and clinical databases 
available for Veterans receiving healthcare in the VHA, and was used to construct an analytic 
dataset consisting of new CLC admissions over fiscal years 2009-2015 for Veterans with LLE/AD. 
The VA Residential History file, which uses VA and Medicare utilization data to track the location 
of Veterans as they transition through different settings of VA and non-VA care, was used to 
identify VHA CLC episodes. The Veterans Affairs (VA) Corporate Data Warehouse (CDW) was 
used to obtain information about VA utilization of care. Medicare fee-for-service claims were used 
to obtain information on non-VHA utilization of care, as all Veterans aged 65 and older are eligible 
to enroll in Medicare to cover the use of non-VHA health services in addition to VHA. The 
Minimum Dataset (MDS) contained comprehensive clinical assessment data on all Veterans at 
admission to VA CLCs over the study time frame. The MDS is a mandatory assessment tool which 
comprehensively assesses nursing home resident upon admission. The assessment is to be 
completed within 14 days of the admission, then quarterly and upon major changes in health status 
of the resident. Domains include demographics, behavior, diagnoses/conditions, functional status, 
cognitive status, nutrition/dental status, mood, continence, and discharge potential. Items 
containing in this dataset can be combined to create validated scales or indices use to measure 
health-related factors. Thus, this dataset was used to identify CLC residents with limited life 
expectancy/advanced dementia at admission, and define a set of covariates on resident prognosis 
and health status. During this study period, there were two available version of the MDS: v2.0 and 
v3.0. Version 3.0 became available in July of 2012 in the VHA. Bar-coded medication 
administration (BCMA) records provided detailed information regarding medication exposure. 
Using BCMA records, we could determine daily medication name and doses, which was useful in 
 18 
determining medication covariates (described in section 2.6), and defining aspirin utilization and 
aspirin discontinuation (described in section 2.4 and 2.5).  Data from the VHA Support Service 
Center (VSSC) were utilized to obtain facility-level factors.   
2.3 Participants 
These data sources were used to identify all Veterans aged 65 years or older who were admitted 
to a VHA CLC for at least 7 days over fiscal year (FY) 2009-2015 with evidence of limited life 
expectancy and/or advanced dementia at admission. CLC episode start and end dates were first 
determined using the RHF. The RHF creates a calendar which describes a patient’s location, 
provider type and service type on any given day within a calendar year. The algorithm used by the 
RHF is hierarchical, first populating this calendar with information regarding inpatient claims, 
then emergency department and observation days, then skilled nursing facility claims, then 
additional NH claims, and finally home health claims. Hospice days are added last, because they 
are not location-specific, such as the other claims listed previously. Instead, hospice can be 
administered either at home or in a facility. Days spent consecutively in one of the above settings 
create an “episodelet” with the RHF for that patient, and the joining of episodelets creates an 
“episode” such as in the case where a patient may transition from a skilled nursing facility to less 
skilled care, while remaining in the same NH.51 For the purpose of this study, an episode was 
created by concatenating adjacent episodelets as long as gaps between episodelets were <7 days. 
Episodes begin when a patient enters the CLC to the time they were discharged (either to home or 
to a hospital for > 7 days, as determined by gaps in episodelets), or died. Death was determined by 
using the VA vital status file. All CLC episodes with a linked MDS admission assessment 
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occurring within the first 30 days of the episode were included (n= 200,333). It was possible for 
multiple episodes to be included over this time frame for a single Veteran.  
These CLC episodes were further limited to include only residents who met at least one of 
three possible criteria for exhibiting LLE/AD at admission. The first criterion for LLE was 
endorsement of the single item available in both v2.0 (item J5c) and v3.0 (item J1400) of the MDS 
which asks providers to state whether or not they believe the nursing home resident has a life 
expectancy of six months or less. This indicator alone has been shown to accurately identify those 
who have poor prognosis and LLE, with sensitivity of 53.2%, and specificity of 88.4%.52  
 
The second criterion for LLE was a score of ≥36 on the MDS Mortality Risk Index – 
Revised (MMRI-R). The MMRI-R is a tool which predicts the likelihood of 6-month mortality 
amongst nursing home residents, and was originally created from measures in the MDS version 
2.0.53 Possible scores range 0-85 points, based on a weighted total of the following MDS items: 
male sex (5 points), admission to a nursing home in the past 3 months (8 points), shortness of 
breath, poor appetite (4 points), weight loss unintentionally in the last 3 months (5 points), heart 
failure (4 points), renal failure (6 points), dehydrated (4 points), cancer (ranging from 2 to 20 point 
based on age at admission), and a short-form ADL scale (with higher scores indicating greater 
dependency). Higher scores on the MMRI-R indicate poorer prognosis and greater likelihood of 
death, with scores 36 showing sensitivity of 34.4% and specificity of 92.2% for predicting 6-
month mortality in non-VA MDS v2.0 assessments.53 Recently, the MMRI-R was adapted to be 
used with MDS version 3.0, as the newer version of the MDS form had revised the phrasing of 
several items used to calculate the MMRI-R score.52 Although most item revisions were minor and 
did not change their intended meaning, two items were subject to more substantive revisions. In 
 20 
version 2.0 the item used for change in mental status included “recent deterioration in cognitive 
status,” while version 3.0 read “acute change in mental status.” The item for poor appetite in 
version 2.0 read “leaves food uneaten” while in version 3.0 it read “poor appetite or overeating.”  
However, recent research showed that using these revised MDS v3.0 items to calculate the MMRI-
R score did not negatively impact the measure’s predictive ability with regard to 6-month 
mortality, with the overall model using the continuous MMRI-R version 3.0 score showing good 
prediction with a c-statistic of 0.81.52 In addition, sensitivity and specificity of the ≥36 cutoff for 
predicting 6-month mortality were 70.5% and 77.1%, respectively.52 
The third criterion for LLE/AD consisted of a score on a cognitive assessment scale 
included in the MDS indicating advanced dementia. Both versions 2.0 and 3.0 of the MDS use 
different assessments of cognition. The MDS version 2.0 uses the Cognitive Performance Scale 
(CPS) with all residents. However, MDS version 3.0 uses the Brief Interview for Mental Status 
(BIMS) with residents who can complete an interview, and the CPS with residents who are unable 
to complete an interview. Both tools have been validated against the Mini-Mental Status 
Examination for identifying severe cognitive impairment indicative of advanced dementia in 
nursing home residents.54-56 The CPS ranges from 0 to 6, with higher scores representing worse 
cognition, and conducted by a trained observer. For the current study, a CPS value of ≥4 was 
considered indicative of advanced dementia, based on prior evidence suggesting good sensitivity 
(84%) and specificity (67%) of this cutoff for identifying severe impairment.56 The BIMS ranges 
from 0 to 15 with lower values representing worse cognition, and is conducted via a patient 
interview. For the current study, a value of 7 or less on the BIMS was considered indicative of 
advanced dementia, based on prior evidence suggesting 83% sensitivity and 92% specificity of 
this cutoff for identifying severe impairment.54, 56  
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Applying these criteria for LLE/AD resulted in identification of 81,273 residents with at 
least one of the three LLE/AD criteria at CLC admission. We then further limited the sample to 
episodes in which the Veteran was aged 65 or older at admission (n=61,137, 75%). Further 
restricting the sample to CLC episodes with a minimum length of stay of at least 7 days resulted 
in 58,782 (96%) episodes.  
 The last step in sample construction was to limit to episodes for Veterans with a history of 
coronary artery disease (CAD) and/or stroke/transient ischemic attack (TIA), and thus were 
considered eligible for use of aspirin for secondary prevention. The history of CAD and/or 
stroke/TIA was determined by searching the VA CDW utilization records and Medicare claims 
for ICD-9 diagnosis codes for these conditions, using validated algorithms from the Chronic 
Condition Data Warehouse, as well as MDS indicators for these conditions (CCW Ischemic Heart 
Disease; CCW Stroke/Transient Ischemic Attack). See table 1 for a complete list of codes used to 
determine history of CAD, stroke and TIA. The final sample for Aim 1 consisted of 37,165 newly 
admitted CLC residents aged ≥65 years with LLE/AD and history of CAD or stroke/TIA at 
admission. 
Aim 2 analyses were further restricted to Veterans meeting the above criteria who had at 
least 14 days of follow-up available in the CLC after the first date on which aspirin use was 
observed, to assess for aspirin discontinuation (n=13,844).  See Figure 2 for a summary of the 
sample construction process.  
 
Table 1: Diagnostic Codes Used to Identify the Primary Cohort 
 Diagnosis Code Algorithm MDS indicators 
Conditions Number/type of claims ICD-9 Codes  
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Coronary Artery 
Disease 
At least 1 of the following 
claim/encounter type in the 
2 years prior to admission:  
• Medicare inpatient 
• Medicare SNF 
• Medicare home 
health  
• Medicare outpatient 
• Medicare carrier 
• VHA inpatient  
• VHA outpatient 
• VHA outpatient fee 
DX 410.00, 410.01, 
410.02, 410.10, 
410.11, 410.12, 
410.20, 410.21, 
410.22, 410.30, 
410.31, 410.32, 
410.40, 410.41, 
410.42, 410.50, 
410.51, 410.52, 
410.60, 410.61, 
410.62, 410.70, 
410.71, 410.72, 
410.80, 410.81, 
410.82, 410.90, 
410.91, 410.92, 
411.0, 411.1, 
411.81, 411.89, 
412, 413.0, 413.1, 
413.9, 414.00, 
414.01, 414.02, 
414.03, 414.04, 
414.05, 414.06, 
414.07, 414.12, 
414.2, 414.3, 414.4, 
414.8, 414.9 (any 
DX on the claim)  
V2.0: I1d 
 
V3.0: I0400 
Stroke/TIA At least 1 of the following 
during the 1 year prior to 
admission date: 
• Medicare inpatient 
• VHA inpatient 
OR 
At least 2 of the following 
(on different dates) during 
the 1 year prior to 
admission date: 
• Medicare 
outpatient 
• Medicare carrier 
• VHA outpatient   
• VHA outpatient 
fee 
 
DX 430, 431, 
433.01, 433.11, 
433.21, 433.31, 
433.81, 433.91, 
434.00, 434.01, 
434.10, 434.11, 
434.90, 434.91, 
435.0, 435.1, 435.3, 
435.8, 435.9, 436, 
997.02 (any DX on 
the claim)  
 
 
V2.0: I1t or I1bb 
 
V3.0: I4500 
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Figure 2: Cohort Construction for Aspirin Receipt 
2.4 Aspirin User Definition 
Aspirin use at admission was determined from BCMA records and was defined as having 
at least 1 day of aspirin use in the first 7 days of CLC episode with a total daily dose of 25-325 
mg. We recognize that the recommended dose of aspirin is 50-325 mg in those with a history of 
stroke or TIA, and a total daily dose of 75-325 mg in those with a history of CAD.4, 5 However, 
we ultimately decided to include those who received 25 mg of aspirin daily as aspirin users because 
of small numbers with this dosing, and to allow for missed or held dosages. The lower end of the 
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dose range of 25 mg was included to account for the use of aspirin/dipyridamole which contained 
25 mg of aspirin per capsule and is dosed twice daily.6, 57 The total daily dose of aspirin was 
calculated by adding all aspirin doses throughout the day that were administered. If a medication 
was not administered on that day (even if an order existed but no doses were actually recorded as 
given), the resident was not considered to be exposed to aspirin.    
2.5 Aspirin Discontinuation 
The aspirin discontinuation analysis was limited to the subgroup of Veterans who met 
criteria for initial aspirin use for secondary prevention in the first week of the CLC stay. 
Discontinuation of aspirin was defined as ≥14 consecutive days without aspirin use after the first 
day aspirin use was observed during the first week of the CLC stay. Veterans were followed for 
discontinuation until death, discharge, or day 91 of the CLC stay. Because the last 14 days of 
follow-up during this window consisted of “immortal time” in which it was not possible to observe 
a gap in aspirin use of 14 days, all Veterans were assigned either a censoring date equal to 14 days 
prior to death, discharge, or day 91 of the stay or a discontinuation date defined as the first day of 
the 14-day gap which qualified them for having discontinued therapy.  
2.6 Covariates 
A number of covariates were included to evaluate the patient-level and facility-level 
characteristics which were hypothesized according to our conceptual model as potential predictors 
 25 
of use of aspirin for secondary prevention at CLC admission, and discontinuation of aspirin after 
CLC admission, respectively.  
 
Socio-demographic factors:  
Age at admission was calculated from the date of birth and admission date. Date of birth was pulled 
from MDS item AA3 from version 2.0 and A0900 from version 3.0. We subsequently categorized 
age into 3 categories for analysis: 65-74, 75-84 and ≥ 85 years. Sex was coded as a binary variable 
as either male or female, captured using MDS item AA2 and A0800 from version 2.0 and 3.0, 
respectively. Race and ethnicity were obtained from MDS items AA4 (v2.0) and A1000A-F (v3.0) 
and categorized into the following categories: white non-Hispanic, Black non-Hispanic, Hispanic, 
or other (consisting of American Indian, Alaska Native, Native Hawaiian, Pacific Islander or 
Asian). Marital status was obtained from MDS items A4 (v2.0) and A1200 (v3.0) and was 
categorized as married or not married (consisting of never married, widowed, separated, and 
divorced).  
Environment of care factors:  
Living arrangement before admission was determined using MDS items AB2 and A1800, from 
versions 2.0 and 3.0 respectively, and categorized as acute hospital, community (private home, 
board/care, assisted living, group home), nursing home, or other (psychiatric hospital, inpatient 
rehabilitation hospital, hospice, or other). Fiscal year of admission was based on the date of 
admission documented in the MDS, as noted above. Recent hospitalization was determined using 
Medicare claims data and VA claims data to determine a hospitalization that occurred within 90 
days of the CLC admission. To capture caregiver factors, next-of-kin (NOK) information recorded 
in the VA electronic health record was abstracted from the VA CDW. This included the 
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relationship of the NOK to the Veteran (spouse, adult child, sibling, other relative, friend or other), 
as well the ZIP code for the NOK’s home address. This ZIP code was then used to calculate the 
distance from the centroid of the NOK’s ZIP code to the CLC, which was ascertained from the 
VA CDW. This continuous variable for distance was then categorized into quartiles of the 
distribution, first for the full study sample and then for the subsample of aspirin users at admission.  
 
Cardiovascular risk factors:  
These risk factors include chronic comorbidities which are associated with CVD, which include: 
diabetes, congestive heart failure, hypertension, hyperlipidemia, recent stroke, recent myocardial 
infarction (MI), recent venous thromboembolism (VTE), atrial fibrillation.58-65  Comorbidities 
were obtained from CDW using ICD9/CPT4 codes as well as in the MDS. A full list of these 
comorbidities is included in table 2.  For the purposes of this analysis, 1 year prior to CLC 
admission was used for the following variables as guidelines typically recommend continuation of 
aspirin for a least one year post-event, if aspirin is prescribed for these events: recent stroke, MI, 
VTE, hyperlipidemia, and atrial fibrillation.5 Body mass index (BMI) was calculated using height 
and weight as recorded on the MDS, and was categorized as underweight (< 18.5 kg/m2), normal 
weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) and obese (>30 kg/m2) based on World 
Health organization BMI categories.66 Smoking status was obtained the MDS. In version 2.0, item 
AC1g asks if in the year prior to the date of entry to this nursing home, use of tobacco products 
was at least daily. In version 3.0, item J1300 asks if the resident is currently using tobacco. Both 
questions offered binary responses of yes or no.  
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Table 2: Diagnostic Codes and Algorithms for Cardiovascular Risk factors and History of Falls and 
Fractures 
 Diagnosis Code Algorithm MDS indicators 
Conditions Number/type of claims ICD-9/CPT4/HCPCS 
Codes 
 
Diabetes At least 1 of the following 
during the 2 years prior to 
admission date: 
• Medicare inpatient 
• Medicare SNF 
• Medicare home health 
• VHA inpatient 
OR 
At least 2 of the following (on 
different dates) during the 2 
years prior to admission date: 
• Medicare outpatient 
• Medicare carrier 
• VHA outpatient 
• VHA outpatient fee 
DX 249.00, 249.01, 
249.10, 249.11, 249.20, 
249.21, 249.30, 249.31, 
249.40, 249.41, 249.50, 
249.51, 249.60, 249.61, 
249.70, 249.71, 249.80, 
249.81, 249.90, 249.91, 
250.00, 250.01, 250.02, 
250.03, 250.10, 250.11, 
250.12, 250.13, 250.20, 
250.21, 250.22, 250.23, 
250.30, 250.31, 250.32, 
250.33, 250.40, 250.41, 
250.42, 250.43, 250.50, 
250.51, 250.52, 250.53, 
250.60, 250.61, 250.62, 
250.63, 250.70, 250.71, 
250.72, 250.73, 250.80, 
250.81, 250.82, 250.83, 
250.90, 250.91, 250.92, 
250.93, 357.2, 362.01, 
362.02, 362.03, 362.04, 
362.05, 362.06, 366.41 
(any DX on the claim) 
 
V2.0: I1a 
V3.0: I2900 
Hypertension At least 1 of the following 
during the 1 year prior to 
admission date: 
• Medicare inpatient 
• Medicare SNF 
• Medicare home 
health 
• VHA inpatient 
OR At least 2 of the following 
(on different dates) during the 1 
year prior to admission date: 
• Medicare outpatient 
• Medicare carrier 
• VHA outpatient 
• VHA outpatient fee 
DX 362.11, 401.0, 401.1, 
401.9, 402.00, 402.01, 
402.10, 402.11, 402.90, 
402.91, 403.00, 403.01, 
403.10, 403.11, 403.90, 
403.91, 404.00, 404.01, 
404.02, 404.03, 404.10, 
404.11, 404.12, 404.13, 
404.90, 404.91, 404.92, 
404.93, 405.01, 405.09, 
405.11, 405.19, 405.91, 
405.99, 437.2 (any DX on 
the claim) 
 
V2.0: I1h 
V3.0: I0700 
Hyperlipidemia From CCW: 
 
  
 28 
272.0, 272.1, 272.2, 272.3, 
272.4; any DX on the claim; at 
least 1 from the following: 
Medicare inpatient 
Medicare SNF 
Medicare home health 
VHA inpatient (including fee) 
 
OR 
At least 2 of the following: 
Medicare outpatient 
Medicare carrier 
VHA outpatient (including fee) 
 
Lookback period is 1 year prior 
to episode start 
 
Atrial fibrillation From CCW: 427.31 (only 1st or 
2nd DX on the claim) 
At least 1 from the following: 
Medicare inpatient 
VHA inpatient (including fee) 
 
OR 
 
At least 2 of the following: 
Medicare outpatient 
Medicare carrier 
VHA outpatient (including fee) 
 
Lookback period is 1 year prior 
to episode start 
 
  
History of 
Venous 
thromboembolism 
Patient has the condition if they 
have at least one code in any 
position in any of the following 
files: 
Medicare inpatient 
VHA inpatient  
Medicare outpatient 
Medicare carrier 
VHA outpatient (including fee) 
 
Lookback period is 1 year prior 
to episode start 
 
415.x (for PE, would 
include 415, 415.0, 415.1, 
451.11, 415.12, 415.13, 
415.19), 451.x and 453.x 
(DVT, would include: 415, 
451.0, 451.1, 451.11, 
451.19, 451.2, 451.8, 
451.81, 451.82, 451.83, 
451.84, 451.89, 451.9,  
453, 453.0, 453.1, 453.2, 
453.3, 453.4, 453.40, 
453.41, 453.42, 453.5, 
453.50, 453.51, 453.52, 
453.6, 453.7, 453.71, 
453.72, 453.73, 453.74, 
453.75, 453.76, 453.77, 
453.79, 453.8, 453.81, 
453.82, 453.83, 453.84, 
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453.85, 453.86, 453.87, 
453.89, 453.9)  
 
 
History of Falls, 
hip fractures or 
other fractures 
a. A) Has one of the following 
ICD-9 diagnosis codes (E880-
888, 820) or 
ICD-9 procedure codes (7855, 
7905, 7915, 7925, 7935, 7965) 
or CPT codes (27227, 27228, 
27230, 27232, 27234,-27236, 
27238, 27240, 27242, 27244-
27246, 27248. These codes must 
be in emergency room visits 
and/or hospitalizations in 
Medicare Part A and B claims or 
VHA CDW in the year prior to 
admission 
 J4a=1 or J4b=1 
or J4c = 1 on 
MDS 2.0 
OR 
J1700A=1 or 
J1700B=1 or 
J1700C=1 or 
J1800=1 on MDS 
3.0 
 
 
Recent 
myocardial 
infarction 
At least 1 inpatient claim in 
VHA or Medicare in year prior 
to admission with DX 410.01, 
410.11, 410.21, 410.31, 410.41, 
410.51, 410.61, 410.71, 410.81, 
410.91 (ONLY first or second 
DX on the claim) 
  
Recent 
stroke/TIA 
At least 1 inpatient or 2 
outpatient/carrier claims in 
VHA or Medicare in year prior 
to admission with DX 430, 431, 
433.01, 433.11, 433.21, 433.31, 
433.81, 433.91, 434.00, 434.01, 
434.10, 434.11, 434.90, 434.91, 
435.0, 435.1, 435.3, 435.8, 
435.9, 436, 997.02 (any DX on 
the claim) 
EXCLUSION: If any of the 
qualifying claims have: 800 <= 
DX Code <= 804.9, 850 <= DX 
Code <= 854.1 in any DX 
position OR DX V57xx as the 
principal DX Code, then 
EXCLUDE. 
  
 
Markers of poor prognosis:  
Fall history was determine by indicators on the MDS or available in CDW and Medicare 
utilization data in the last 180 days prior to CLC admission. In MDS version 2.0, the item was J4a-
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c, while version 3.0 utilized item J1700A-C and item J1800. ICD9 codes are included in table 2, 
along-side ICD9 and MDS codes for cardiovascular risk factors.67, 68 Variables that can be 
indicative of poor prognosis were determined using MDS (in version 2.0 and version 3.0, 
respectively) and include: history of cancer (I1PP and I0100), swallowing problems (K1B and 
K0100A-D), IV tube feeding (K5B and K0500A), mechanical diets (K5C and K0500C), food left 
uneaten or poor appetite (K4C and D0200E2), recent weight loss (K3A and K0300), shortness of 
breath (J1L and J1100A-C), recent changes in cognitive status (B6 and C1600), dehydration (J1C 
and J1550C), renal insufficiency (I1QQ and I1500), and pain at admission (J2A and J0300).  
Behavioral problems were assessed using the Aggressive Behavior Scale69, which is based 
on the sum of 4 MDS items (verbally abusive [E4Ab/E0200B]; physically abusive 
[E4Ac/E0200A]; socially inappropriate/disruptive behavior [E4Ad/E0200C]; resists care 
[E4Ae/E0800]). Possible scores can range from 0 to 12 and are categorized into 4 categories: 0 
(no behavioral problems), 1-2 (moderate problems), 3-5 (severe problems), >5 (very severe 
problems). Dependency in activities of daily living (ADLs) was assessed using the ADL-short 
form70 and was scored by using the mean value of four ADLs item included on the MDS (toilet 
use, personal hygiene, eating and locomotion on unit), with higher scores indicating higher level 
of dependence. Continuous scores were categorized as 0 to < 1, ≥1 to <2 , ≥ 2 to <3 , ≥ 3  to < 4, 
and 4 for analysis.  
At admission to the CLC, whether or not a patient is documented as being near the end of 
life may be documented in several ways: 1) endorsement on the admission MDS of item J5c/J1400 
for “end-stage disease, less than 6 months to live”; 2) indication on the admission MDS of hospice 
use within the past 14 days (endorsement of item P1Ao in MDS 2.0 and either item O0100K1 or 
O0100K2 in MDS 3.0), and/or 3) admission to a hospice bed within the CLC, as indicated in the 
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VA CDW treating specialty movement files. As such, we created one summary variable that was 
coded as yes if any of these criteria were met and no if no criteria were met. Finally, total 
comorbidity burden was assessed using the Elixhauser comorbidity index which assesses the 
presence/absence of 30 conditions.71 We created a variable representing the total number of 
Elixhauser conditions, excluding diabetes and diabetes with complications, and hypertension and 
hypertension with complications, as diabetes and hypertension were already captured using 
established claims-based algorithms, as described above.  We then categorized this count into the 
following categories: 0-1, 2-3, 4-5, or ≥ 6 comorbid conditions.  
 
Facility level characteristics: 
Facility level factors included staff turnover rates, facility bed size, facility complexity, U.S census 
region, and rurality of the CLC. Facility bed size, health care provider turnover rates, and facility 
complexity were all obtained from VSSC website and linked to CLC episodes using VHA parent 
station identifiers and FY of admission. VSSC data is captured at the VHA parent station level, 
and there can be more than one CLC per parent station. Thus, patients at two different CLCs, with 
the same parent station, could have the same values available, even though they were in two 
different CLCs.  Bed size and facility complexity level was available for FY11 and FY14 only, so 
CLC episodes were assigned a bed size and complexity level using the closest value available in 
time (i.e., residents admitted in FY09-11 were assigned the bed size and complexity level of the 
facility as determined at FY11, and residents in FY12-15 were assigned the bed size and 
complexity level of the facility in FY14). Turnover rates were available for FY11-15, thus turnover 
rates for FY09-11 were assumed to be the same as the FY11 value; and FY11-15 were matched to 
their appropriate turnover rate. This continuous variable for turnover rate was categorized by 
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quartiles of the distribution, first for the full study sample and then for the subsample of aspirin 
users at admission.  
 Bed size was transformed from a continuous variable to a categorical variable (<60 beds, 
60-120 beds, >120 beds per facility) for analysis.  Facility complexity level range from 1a to 3 by 
level of complexity. Complexity level 1a includes facilities with the largest levels of volume, 
patient risk, teaching and research, number and breadth of physician specialists, and level 5 
intensive care units (ICUs). ICU levels range from 1 to 5, where high levels represent more 
complex ICUs. Complexity level 1b include facilities with large levels of volume, patient risk, 
teaching and research, and level 4 and 5 ICUs. Complexity level 1c facilities are similar to level 
1b, however they only have level 4 ICUs. Complexity level 2 facilities have medium level 
volumes, patient risk, teaching and research activities, and level 3 and 4 ICUs. Complexity level 3 
facilities include the lowest level of patient complexity, smallest level of volume, little or no 
teaching or research activities, lowest numbers and breadth of physician specialists, and level 1 or 
2 ICUs. Census region from which the CLC was located, and urban influence code, which is a 
measure of rurality, were obtained by linking the zip code from the CLC to external data from the 
US census and the Area Health Resource File, respectively.72, 73   
 
Bleeding risk factors  
For this study, variables for use of medications which increase or decrease the risk of bleeding 
outcomes are included. Medications which were prescribed on the first or second day of the CLC 
admission were included and obtained from BCMA data. Medications include: anti-thrombotic 
agents, non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), and H2- 
receptor antagonists. Originally, we had planned to assess use of COX-2 inhibitors and 
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gastrointestinal protective agents at baseline (due to possible effects on bleeding risk) but too few 
individuals were observed to be taking these medications to include in the final analysis. With such 
small numbers, it is very difficult to assess the effect of a variable on an outcome where the 
variation is incredibly small, and there is also concern for privacy when values are <11.  
 
2.7 Statistical Analysis 
Descriptive statistics were used to determine the frequency of aspirin use and frequencies 
of covariates amongst the entire cohort. Descriptive statistics were also used to describe the 
frequency of covariates amongst those taking aspirin at admission who were followed for 
subsequent aspirin discontinuation. For all covariates with missing values, hotdeck imputation was 
used to impute values for those missing variable values.74 Those imputed variable values were 
used as covariates in all analysis moving forward, and differences in variable distributions can be 
seen on table 1. 
 
For Aim 1, the dependent variable is aspirin use at admission, which is defined as a binary 
outcome (yes/no) indicating any receipt of aspirin in the dosing range in the first 7 days of CLC 
visit. Univariable and multivariable logistic regression models were estimated to determine the 
variables significantly associated with higher or lower odds of aspirin use in the first week of the 
CLC, providing unadjusted and adjusted estimates, respectively. In all cases, clustering at the 
facility level was accounted for; this adjusted the standard error to account for intragroup 
correlation at the parent station (facility) level.   
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For Aim 2, the dependent variable was aspirin discontinuation, as previously described 
above. A cumulative incidence competing risk (CICR) method was used to determine the 
probability of an event (i.e., deprescribing) prior to censoring. First this was done to determine the 
overall incidence of aspirin discontinuation, and secondarily was performed using an indicator for 
“documentation of limited prognosis at admission” (as described previously) as the primary 
independent variable, to determine if the hazard of discontinuing was different between those with 
positive indicator of limited prognosis versus those without this indicator, adjusting for all other 
variables in the model. This was done to determine if the knowledge that one has limited life 
expectancy or the treating specialty of hospice modifies the relationship of patient and facility 
factors to deprescribing. Palliative care and hospice care is significantly different than non-
hospice/palliative care. Most guidelines which recommend against potentially inappropriate 
medication (i.e., Beers Criteria, STOPP/START) explicitly indicate that the guidelines do not 
pertain to those on hospice or palliative care given differences in goals of care.75-77 It is thus 
plausible that the likelihood of aspirin discontinuation may vary amongst those who have explicit 
documentation of limited prognosis versus those who do not.  
Survival analysis allowing for the competing risk of death was chosen due to the high risk 
of death in these population (n=2,524, 18% of the qualifying cohort for discontinuation were 
censored due to death prior to CLC discharge), given that everyone in this cohort qualified as 
having LLE and/or advanced dementia (AD). Death is thus a competing risk, and using the CICR 
method has been shown to be more robust to differences in the outcome of interest over time than 
the Kaplan Meier approach. Death was the only censoring point used as a competing risk, because 
once someone has died, they are no longer eligible to be discontinued, and no longer have the same 
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probability of discontinuation as someone who remained in the study. Alternatively, being 
discharged from the CLC or reaching the end of the allotted study period does not compete with 
discontinuation, as discontinuation can occur after the discharge or at the end of the study period.78 
Standard survival analysis assumes that once a patient has been censored, they otherwise would 
still be at the same risk of the event (in this case deprescribing of aspirin), had they not been 
censored. Noordzij, et al recommend that in the event of a prognostic research aims (i.e., that you 
are predicting the probability of an outcome at a given time), such as in the case of this research, 
one should not conduct unadjusted analysis using Kaplan-Meier approach when competing risks 
occur because the independent censoring assumption is violated (patients will not be at the same 
risk of deprescribing if they die versus those who do not die and experience another competing 
event such as discharge from the CLC). Instead, one should use the CICR method to determine the 
probability of discontinuation before time, t. The rationale here is that Kaplan-Meier methods can 
often overestimate both the event of interest (discontinuation) and the competing risk while event-
free survival (i.e. probability of not being discontinued) remains unbiased. 
The CICR method was thus used to determine the cumulative incidence of discontinuation, 
with and without stratification by hospice status.  The program was set to indicate discontinuation 
as the event of interest, and the competing risk was death. We subsequently modeled the 
unadjusted and adjusted associations of each covariate described above using Fine and Gray 
competing risk subdistribution hazard models.79 All standard errors were adjusted for intragroup 
correlation at the parent station level by adding the parent station as a cluster variable. The outcome 
of a CICR method is not a hazard ratio, as is the output for Cox proportional hazard models, but 
instead subdistribution hazard ratios (SDHR). An interaction term of time was used to test the 
assumption of proportional hazards. This test is determining if the effect of the variable of interest 
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changes over time. In the event of violations of proportional hazards, the reporting of SDHRs will 
indicate an average effect of that variable on the hazard of discontinuation, as opposed to an 
instantaneous incidence of the event. Below, we report both unadjusted SDHRs as well as SDHRs 
adjusted for all other variables in the model, first for the entire discontinuation sample and then 
after stratifying this sample by the indicator of documentation of limited prognosis/hospice at 
admission, as described previously.   
2.8 Sensitivity Analysis 
We conducted a supplemental analysis to determine the sensitivity of our results to the 
length of the gap in aspirin use chosen to define discontinuation of therapy. Specifically, we 
conducted sensitivity analysis using a longer gap in therapy to define discontinuation, that is,  30 
consecutive days without aspirin therapy rather than 14 days. In the sensitivity analysis, the 
Veterans were censored at either the new definition of aspirin discontinuation, 30 days before 
discharge from CLC, 30 days before death, and at day 91 of the CLC episode. The same statistical 
analysis approach was completed for the sensitivity analysis. Thirty days was chosen as the 
alternative gap length because this is commonly used when measuring discontinuation to 
medications when prescription refill records are available rather than daily BCMA data.80-82   
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3.0 Results 
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3.1 Demographics of Overall Sample 
A total of 37,165 older Veterans qualified for this sample by having LLE/AD and either CAD or 
a history of stroke/TIA. Descriptive characteristics of the sample are shown in Table 1, before 
and after imputation of missing values. The cohort was predominantly male (98%), white, non-
Hispanic (78%), and 75 years of age (73%). A majority of the cohort came from an acute 
hospital prior to their CLC admission (68%), and qualified as having LLE by a MMRI score of 
36 (77%). A majority of the cohort had only one qualifying physical condition 
(CAD/Stroke/TIA) (78%) – of which CAD was the predominant qualifying condition (88%). 
Approximately 44% had some documentation of limited prognosis or hospice use at admission. 
This included 39% of the sample had an endorsement on the admission MDS of “end-stage 
disease, less than 6 months to live”, and 32% of the sample were admitted to a hospice treating 
specialty in the 14 days prior to admission (data not shown in table). In addition, about 37% had 
received palliative care or a hospice consult in the year prior to their CLC admission. The most 
common comorbidities included diabetes (50%), congestive heart failure (46%), hypertension 
(92%), hyperlipidemia (67%), and cancer (38%), and over a third (38%) had >5 Elixhauser 
conditions. A majority of the cohort had no history of smoking (90%), and 43% had a normal 
BMI. Falls and fractures in the 180 days prior to admission were common, occurring in 46% of 
the sample. About 13% were prescribed an additional anti-platelet (other than aspirin), 42% were 
prescribed an anti-thrombotic agent, and almost half were prescribed a proton pump inhibitor at 
CLC admission (48%).   
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Table 3. Baseline Characteristics of Older Adult Veterans in the Community Living Center.  
 Full Sample 
(N= 37,165) 
Full Sample with Imputed 
Variables 
(N=37,165) 
Demographics n (%) n (%) 
Age at admission   
   65-74 10,138 (27.3) 10,138 (27.3) 
   75-84 14,116 (38.0) 14,116 (38.0) 
   ≥85 12,911 (34.7) 12,911 (34.7) 
Sex   
   Male 36,610 (98.5) 36,610 (98.5) 
   Female 555 (1.5) 555 (1.5) 
Race/ethnicity   
   White 29,117 (78.4) 29,314 (78.9) 
   Black 5,362 (14.4) 5,395 (14.5) 
   Hispanic 1,801 (4.9) 1,814 (4.9) 
   Other  636 (1.7) 642 (1.7) 
   Missing 249 (0.7) - 
Marital status   
   Married 18,155 (48.9) 18,167 (48.9) 
   Not married 18,986 (51.1) 18,998 (51.1) 
   Missing 24 (0.06) - 
   
Environment of Care Factors   
Fiscal year of admission   
   2009 4,755 (12.8) 4,755 (12.8) 
   2010 4,904 (13.2) 4,904 (13.2) 
   2011 5,162 (13.9) 5,162 (13.9) 
   2012 5,286 (14.2) 5,286 (14.2) 
   2013 5,724 (15.4) 5,724 (15.4) 
   2014 5,742 (15.5) 5,742 (15.5) 
   2015 5,592 (15.0) 5,592 (15.0) 
Living arrangement before 
admission 
  
   Acute hospital 25,143 (67.7) 25,144 (67.7) 
   Community  9,074 (24.4) 9,075 (24.4) 
   Nursing home 1,932 (5.2) 1,932 (5.2) 
   Other 1,014 (2.7) 1,014 (2.7) 
   Missing 2 (0.01) - 
Hospitalization in 90 days prior to 
admission 
21,728 (58.5) 21,728 (58.5) 
Next of kin relationship to the 
Veteran 
  
   Spouse 15,031 (40.4) 15,038 (40.5) 
   Child 15,296 (41.1) 15,302 (41.2) 
   Sibling 3,290 (8.9) 3,290 (8.9) 
   Other relative 1,594 (4.3) 1,596 (4.3) 
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Friend or other specified   
person of unknown relation 
1,939 (5.2) 1,939 (5.2) 
Missing 15 0.04) - 
Distance from next of kin ZIP code 
centroid to the CLC 
  
Quartile 1  8,969 (24.1) 9,288 (25.0) 
Quartile 2  8,969 (24.1) 9,317 (25.1) 
Quartile 3  8,967 (24.1) 9,265 (24.9) 
Quartile 4  8, 968 (24.1) 9,295 (25.0) 
Missing 1,292 (3.5) - 
   
Cardiovascular Risk Factors   
Number of qualifying conditions 
(CAD, stroke/TIA) 
  
1 28,942 (77.9) 28,942 (77.9) 
2 8,223 (22.1) 8,223 (22.1) 
Diabetes 18,530 (49.9) 18,530 (49.9) 
Congestive heart failure 17,245 (46.4) 17,245 (46.4) 
Hypertension 34,068 (91.7) 34,068 (91.7) 
Hyperlipidemia  24,706 (66.5) 24,706 (66.5) 
Venous thromboembolism  5,087 (13.7) 5,087 (13.7) 
Atrial fibrillation last year 7,012 (18.9) 7,012 (18.9) 
Recent Myocardial Infarction in the 
last year 
2,120 (5.7) 2,120 (5.7) 
Recent Stroke in the last year 9,845 (26.5) 9,845 (26.5) 
Current Smoker   
  No 33,459 (90.0) 34,148 (91.9) 
  Yes 2,950 (7.9) 3,017 (8.1) 
  Missing 756 (2.0) - 
Body Mass Index (kg/m2)   
Normal or healthy weight 
(18.5 to <25.0) 
16,135 (43.4) 16,718 (45.0) 
Underweight (<18.5) 3,595 (9.7) 3,712 (10.0) 
Overweight (25.0 to <30.0) 9,843 (26.5) 10,221 (27.5) 
Obese (≥30) 6,285 (16.9) 6,514 (17.5) 
Missing 1,307 (3.5) - 
   
Markers of Poor Prognosis   
Advanced dementia 13,155 (35.4) 13,155 (35.4) 
Documentation of limited prognosis 
or hospice use at admission 
16,394 (44.1) 16,516 (44.4) 
Number of Elixhauser conditions   
0-1 2,986 (8.0) 2,986 (8.0) 
2-3 8,746 (23.5) 8,746 (23.5) 
4-5 11,184 (30.1) 11,184 (30.1) 
>5 14,249 (38.3) 14,249 (38.3) 
Recent weight loss 14,571 (39.2) 14,571 (39.2) 
Leaves food uneaten 16,296 (43.8) 16,296 (43.8) 
Renal failure 6,679 (18.0) 6,679 (18.0) 
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Dehydration 559 (1.5) 559 (1.5) 
Acute change in mental status 4,600 (12.4) 4,600 (12.4) 
Shortness of breath  14,398 (38.7) 14,398 (38.7) 
Cancer 14,371 (38.7) 14,371 (38.7) 
Activities of Daily Living (ADL) 
score 
  
0 - <1 3,630 (9.8) 3,630 (9.8) 
1 to <2 7,387 (19.9) 7,387 (19.9) 
2 to <3 11,236 (30.2) 11,236 (30.2) 
3 to <4 9, 488 (25.5) 9, 488 (25.5) 
4 5,424 (14.6) 5,424 (14.6) 
Aggressive Behavior   
 None  30,518 (82.1) 30,872 (83.1) 
 Moderate  4,031 (10.9) 4,077 (11.0) 
 Severe  1,640 (4.4) 1,652 (4.5) 
 Very severe  560 (1.5) 564 (1.5) 
 Missing  416 (1.1) - 
IV feeding tube in place 3,572 (9.6) 3,572 (9.6) 
On Mechanical Diet 16,036 (43.2) 16,036 (43.2) 
Swallowing Problems  7,773 (20.9) 7,773 (20.9) 
Presence of any pain (n, % yes)   
Yes 24,573 (66.1) 26, 275 (70.7) 
No 10,204 (27.5) 10,890 (29.3) 
Missing 2,388 (6.4) - 
History of falls, hip fracture, and 
other fractures in past 180 days  
  
Yes  17,216 (46.3) 17,709 (47.7) 
No  18,981 (51.1) 19,456 (52.4) 
Missing 968 (2.6) - 
 
Facility Factors 
US Census region of the CLC   
 Northeast 6,381 (17.2) 6,381 (17.2) 
 Midwest 10,762 (29.0) 10,762 (29.0) 
 South 13,024 (35.0) 13,024 (35.0) 
 West 6,998 (18.8) 6,998 (18.8) 
Urban Influence Code for the CLC   
   Large metro 16,935 (45.6) 16,935 (45.6) 
   Small metro 13,269 (35.7) 13,269 (35.7) 
   Micropolitan 2,938 (7.9) 2,938 (7.9) 
   Noncore rural 4,023 (10.8) 4,023 (10.8) 
Complexity Level of the parent 
station 
  
   1a (Highest) 14,003 (37.8) 14,042 (37.8) 
   1b   4,553 (12.3) 4,560 (12.3) 
   1c 6,934 (18.7) 6,933 (18.7) 
   2 5,039 (13.6) 5,049 (13.6) 
   3 (Least Complex) 6,564 (17.7) 6,581 (17.7) 
   Missing 82 - 
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Bed Size of CLC   
   <60 beds 15,715 (15.4) 15,715 (15.4) 
   60-120 beds 13,495 (36.3) 13,495 (36.3) 
   >/= 120 beds 17,955 (48.3) 17,955 (48.3) 
Physician turnover rate   
Quartile 1 9,306 (25.0) 9,306 (25.0) 
Quartile 2 9,652 (26.0) 9,652 (26.0) 
Quartile 3 8,952 (24.1) 8,952 (24.1) 
Quartile 4 9,255 (24.9) 9,255 (24.9) 
Nurse turnover rate   
Quartile 1 9,427 (25.4) 9,427 (25.4) 
Quartile 2 9,165 (24.7) 9,165 (24.7) 
Quartile 3 9,427 (25.4) 9,427 (25.4) 
Quartile 4 9,146 (24.6) 9,146 (24.6) 
Pharmacist turnover rate   
Quartile 1 9,337 (25.1) 9,337 (25.1) 
Quartile 2 9,350 (25.2) 9,350 (25.2) 
Quartile 3 9,193 (24.7) 9,193 (24.7) 
Quartile 4 9,285 (25.0) 9,285 (25.0) 
Practical nurse turnover   
Quartile 1 9,316 (25.1) 9,316 (25.1) 
Quartile 2 9,270 (24.9) 9,270 (24.9) 
Quartile 3 9,325 (25.1) 9,325 (25.1) 
Quartile 4 9,254 (24.9) 9,254 (24.9) 
Psychology Turnover   
Quartile 1 9,443 (25.4) 9,443 (25.4) 
Quartile 2 9,225 (24.8) 9,225 (24.8) 
Quartile 3 9,239 (24.9) 9,239 (24.9) 
Quartile 4 9,258 (24.9) 9,258 (24.9) 
Medications Prescribed Which May Impact Aspirin Prescribing 
Anti-platelet 4,750 (12.8) 4,750 (12.8) 
Anti-thrombotic Agents 15,690 (42.2) 15,690 (42.2) 
H2- Receptor Antagonists 3,461 (9.3) 3,461 (9.3) 
Proton Pump Inhibitors 17,993 (48.4) 17,993 (48.4) 
NSAIDs 1,251 (3.4) 1,251 (3.4) 
 
 
3.2 Aspirin Use in the Overall Sample 
Aspirin was received by 48% of the sample during the first week of the CLC stay 
(N=17,973). A majority of the sample who met criteria for initial aspirin use did so on day 1 (54%) 
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or day 2 (38%) of the CLC stay (Table 4). The most commonly prescribed dose of aspirin for 
secondary prevention in the first 7 days of CLC admission was 81 milligrams, prescribed in 72% 
of the overall sample, including 77% of those with CAD only, 58% of those with stroke/TIA only, 
and 65% of those with both CAD and stroke/TIA (Table 5).  
 
Table 4: Date of Community Living Center (CLC) Stay When Aspirin was Prescribed and Met Criteria for 
Secondary Prevention 
 
  
 
 
 
Table 5: Aspirin Dosing on the Index Date by Diagnosis Amongst Aspirin User 
 
CLC day N = 17,973 (%) 
1 9,762 (54.3) 
2 6,770 (37.7) 
3 965 (5.4) 
4 179 (1.0) 
5 129 (0.7) 
6 87 (0.5) 
7 81 (0.5) 
Aspirin Dose (mg) Total Cohort 
N= 17,973 
(%) 
CAD only 
N = 11,751 (%) 
Stroke/TIA only 
N= 1,856 (%) 
CAD and  
Stroke/TIA 
N= 4,366 (%) 
25 to < 81 704 (3.9) 114 (1.0) 232 (12.5) 358 (8.2) 
81 12,932 (72.0) 9,013 (76.7) 1,073 (57.8) 2,846 (65.2) 
>81 to <162 113 (0.6) 20 (0.2) 27 (1.5) 66 (1.5) 
162 384 (2.1) 254 (2.2) 36 (1.9) 94 (2.2) 
>162 to <325 123 (0.7) 58 (0.5) 20 (1.1) 45 (1.0) 
325 3717 (20.7) 2,292 (19.5) 468 (25.2) 957 (21.9) 
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3.3 Factors Predicting Receipt of Aspirin for Secondary Prevention of Cardiovascular 
Disease  
Results of the univariable and multivariable logistic regression models are shown in Table 
6. As the goal of this analysis is to identify factors significantly associated with initial aspirin use 
at admission, independent of all other factors, we highlight the results from the fully adjusted 
multivariable model here. Amongst the demographic factors associated with aspirin receipt, age 
85 years was associated with higher odds of aspirin receipt (aOR 1.11, 95% CI 1.03-1.19), and 
female sex (aOR 0.73, 95% CI 0.60-0.89) and Hispanic ethnicity (aOR 0.75, 95% CI 0.61-0.92) 
were associated with lower odds of aspirin receipt. The only environment of care factor associated 
with higher odds of aspirin receipt included having a friend or other specified person of unknown 
relation as the NOK opposed to a spouse as the NOK (aOR, 1.16, 95% CI 1.01-1.34). A number 
of cardiovascular risk factors were associated with higher odds of aspirin receipt, including having 
both qualifying conditions (CAD and stroke/TIA) (aOR 1.17, 95% CI 1.09-1.26), diabetes (aOR 
1.10, 95% CI 1.05-1.16), congestive heart failure (aOR 1.36, 95% CI 1.27-1.45), hypertension 
(aOR 1.24, 95% CI 1.13-1.36), hyperlipidemia (aOR 1.21, 95% CI 1.14-1.28), a recent myocardial 
infarction (aOR 1.99, 95% CI 1.79-2.22), and being a current smoker (aOR 1.17, 95% CI 1.08-
1.26). Cardiovascular risk factors associated with lower odds of aspirin receipt included having a 
VTE in the year prior to CLC admission (aOR 0.67, 95% CI 0.62-0.72), having a diagnosis of 
atrial fibrillation (aOR 0.84, 95% CI 0.78-0.90), and being underweight versus normal or health 
weight (aOR 0.90, 95% CI 0.83-0.98).  
Several markers of poor prognosis were associated with lower odds of aspirin receipt at 
admission, including documentation of limited prognosis or hospice use at admission (aOR 0.51, 
95% CI 0.48-0.55), receipt of palliative care consult or hospice care in year prior to admission 
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(aOR 0.83, 95% CI 0.78-0.88), having 5 or more Elixhauser comorbidities versus 0-1 
comorbidities (aOR 0.88, 95% CI 0.79-0.97), recent weight loss (aOR0.94, 95% CI 0.89-0.99), 
leaving food uneaten (aOR, 0.93, 95% CI 0.87-0.99), dehydration noted on MDS (aOR 0.80, 95% 
CI 0.68-0.95), cancer (aOR 0.75, 95% CI 0.71-0.79), requiring an intravenous feeding tube (aOR 
0.88, 95% CI 0.81-0.95), ADL score of 3 to <4 (aOR 0.85, 95% CI 0.78-0.92) or 4 (aOR 0.71, 
95% CI 0.64-0.79) versus 0 to <1, and pain documented on admission (aOR 0.92, 95% CI 0.87-
0.97). Shortness of breath documented on admission (aOR 1.07, 95% CI 1.02-1.13) and having 
severe behavioral issues (aOR 1.20, 95% CI 1.09-1.31) or very severe behavioral issues (aOR 1.23, 
95% CI 1.03-1.47) versus no aggressive behaviors documented at admission were associated with 
higher odds of aspirin receipt 
Amongst facility level factors, receiving care the West (aOR 0.80, 95% CI 0.68-0.93)  
versus the Northeast, and  residing in a complexity level 2 versus 1a facility (aOR 0.88, 95% CI, 
0.77-1.00) were facility level factors associated with lower odds of receipt of aspirin. Facility 
factors associated with higher odds of aspirin receipt included being cared for in a small 
metropolitan area (aOR 1.13, 95% CI 1.02-1.25) or a micropolitan area (aOR 1.16, 95% CI 1.05-
1.29) versus a large metropolitan area.  
In addition, current use of other medications at admission that might modify the 
effectiveness or safety of aspirin use was also associated with higher odds of aspirin use, including 
being prescribed another anti-platelet agent (aOR 1.92, 95% CI 1.77-2.09), anti-thrombotic agent 
(aOR 1.35, 95% CI 1.25-1.46), H2-Receptor agonist (aOR 1.27, 95% CI 1.17-1.38), proton pump 
inhibitor (aOR 1.23, 95% CI 1.17-1.29) or NSAID (aOR 1.15, 95% CI 1.01-1.31). See table 6 
below for all results, and figures 3 and 4 for tornado plots which display factors predicting higher 
and lower odds of aspirin receipt, respectively.  
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Table 6: Unadjusted and Adjusted Odds of Aspirin Receipt for Secondary Prevention of Cardiovascular 
Disease 
 Unadjusted Adjusted 
Demographics OR (95% CI) OR (95% CI) 
Age at admission   
   65-74 Ref Ref 
   75-84 1.03 (0.97-1.09) 1.05 (0.99-1.11) 
   ≥85 1.04 (0.98-1.11) 1.11 (1.03-1.19)** 
Sex   
   Female 0.65 (0.54-0.78)** 0.73 (0.60-0.89)** 
Race/ethnicity   
   White Ref Ref 
   Black 1.00 (0.91-1.10) 1.02 (0.93-1.11) 
   Hispanic 0.68 (0.51-0.91)** 0.75 (0.61-0.92)** 
   Other  1.02 (0.81-1.28) 1.11 (0.90-1.37) 
Marital status   
   Married 1.00 (0.95-1.05) 0.98 (0.91-1.07) 
   
Environment of Care Factors   
Fiscal year of admission   
   2009 Ref Ref 
   2010 0.99 (0.91-1.07) 1.02 (0.94-1.11) 
   2011 0.97 (0.90-1.04) 0.99 (0.91-1.06) 
   2012 1.00 (0.91-1.10) 0.98 (0.89-1.09) 
   2013 0.98 (0.89-1.08) 0.91 (0.82-1.01) 
   2014 1.01 (0.93-1.11) 0.95 (0.85-1.06) 
   2015 0.93 (0.86-1.01) 0.86 (0.77-0.96)* 
Living arrangement before 
admission 
  
Acute hospital Ref Ref 
Community 0.95 (0.88-1.02) 1.02 (0.95-1.08) 
Nursing home 0.89 (0.78-1.00) 1.05 (0.95-1.16) 
Other 0.71 (0.60-0.84)** 0.93 (0.81-1.06) 
Hospitalization in 90 days prior to 
admission 
1.00 (0.96-1.05) 1.00 (0.95-1.05) 
Next of kin relationship to the 
Veteran¥ 
  
   Spouse Ref Ref 
   Child 1.04 (0.99-1.10) 1.05 (0.97-1.13) 
   Sibling 0.98 (0.89-1.07) 1.03 (0.92-1.15) 
   Other relative 1.00 (0.90-1.12) 1.06 (0.93-1.20) 
   Friend or other specified 
person of unknown relation 
1.14 (1.02-1.28)* 1.16 (1.01-1.34)* 
Distance from next of kin ZIP code 
centroid to the CLC¥ 
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   Quartile 1   Ref Ref 
   Quartile 2   1.02 (0.95-1.09) 1.01 (0.94-1.07) 
   Quartile 3  1.03 (0.96-1.10) 0.95 (0.90-1.02) 
   Quartile 4  1.17 (1.09-1.26)** 1.06 (0.99-1.13) 
   
Cardiovascular Risk Factors   
Number of qualifying conditions 
(CAD, stroke/TIA, and/or diabetes) 
  
1 Ref Ref 
2 1.28 (1.21-1.35)** 1.17 (1.09-1.26)** 
Diabetes 1.31 (1.24-1.38)** 1.10 (1.05-1.16)** 
Congestive heart failure 1.51 (1.43-1.60)** 1.36 (1.27-1.45)** 
Hypertension 1.59 (1.45-1.74)** 1.24 (1.13-1.36)** 
Hyperlipidemia 1.39 (1.32-1.47)** 1.21 (1.14-1.28)** 
Venous Thromboembolism  0.70 (0.66-0.75)** 0.67 (0.62-0.72)** 
Atrial Fibrillation  0.97 (0.90-1.04) 0.84 (0.78-0.90)** 
Recent stroke  1.07 (1.01-1.14)* 0.94 (0.87-1.01) 
Recent MI  2.38 (2.15-2.62)** 1.99 (1.79-2.22)** 
Current Smoker 1.10 (1.02-1.19)* 1.17 (1.08-1.26)** 
Body Mass Index    
Normal or healthy weight 
(18.5 to <25.0) 
Ref Ref 
Underweight (<18.5) 0.74 (0.68-0.80)** 0.90 (0.83-0.98)* 
Overweight (25.0 to <30.0) 1.15 (1.10-1.21)** 1.00 (0.95-1.06) 
Obese (≥30) 1.37 (1.28-1.47)** 1.03 (0.97-1.10) 
   
Factors indicating limited prognosis   
Documentation of limited prognosis 
or hospice use at admission 
0.36 (0.34-0.39)** 0.51 (0.48-0.55)** 
Receipt of a palliative care consult 
or hospice care in year prior to 
admission  
0.50 (0.47-0.53)** 0.83 (0.78-0.88)** 
Number of Elixhauser conditions   
0-1 Ref Ref 
2-3 1.01 (0.93-1.10) 1.00 (0.91-1.09) 
4-5 0.99 (0.89-1.09) 0.91 (0.82-1.02) 
>5 1.04 (0.95-1.14) 0.88 (0.79-0.97)* 
Advanced dementia 0.89 (0.84-0.95)** 0.99 (0.93-1.06) 
Recent weight loss 0.92 (0.88-0.97)** 0.94 (0.89-0.99)** 
Leaves food uneaten 0.74 (0.68-0.80)** 0.93 (0.87-0.99)* 
Renal failure 1.30 (1.22-1.38)** 0.99 (0.93-1.05) 
Dehydration 0.64 (0.54-0.76)** 0.80 (0.68-0.95)** 
Acute change in mental status 0.73 (0.67-0.80)** 0.95 (0.87-1.03) 
Shortness of breath  
 
1.11 (1.04-1.18)** 1.07 (1.02-1.13)** 
Cancer 0.63 (0.59-0.67)** 0.75 (0.71-0.79)** 
Swallowing Problems 0.78 (0.75-0.82)** 0.96 (0.90-1.02) 
IV feeding tube 0.83 (0.76-0.91)** 0.88 (0.81-0.95)** 
Mechanical diet  0.88 (0.83-0.92)** 1.05 (1.00-1.10) 
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ADL short form score   
0 - <1 Ref Ref 
1 to <2 1.17 (1.10-1.26)** 1.03 (0.95-1.12) 
2 to <3 1.04 (0.97-1.12) 0.96 (0.88-1.04) 
3 to <4 0.76 (0.69-0.83)** 0.85 (0.78-0.92)** 
4 0.53 (0.48-0.59)** 0.71 (0.64-0.79)** 
Aggressive Behavior   
None Ref Ref 
Moderate  1.08 (1.00-1.16) 1.05 (0.97-1.13) 
Severe  1.15 (1.04-1.26)** 1.20 (1.09-1.31)** 
Very severe 1.13 (0.94-1.36) 1.23 (1.03-1.47) 
Presence of any pain  0.81 (0.76-0.87)** 0.92 (0.87-0.97)** 
History of falls, hip fracture, and 
other fractures in past 180 days  
1.06 (1.01-1.11)* 1.01 (0.97-1.05) 
   
Facility Factors   
US Census region of the CLC   
Northeast Ref Ref 
Midwest 1.27 (1.09-1.49)** 1.06 (0.93-1.19) 
South 0.97 (0.81-1.16) 0.93 (0.82-1.06) 
West 0.87 (0.70-1.07) 0.80 (0.68-0.93)** 
Urban Influence Code for the CLC   
Large metro Ref Ref 
Small metro 1.08 (0.95-1.23) 1.13 (1.02-1.25)* 
Micropolitan 1.02 (0.82-1.26) 1.16 (1.05-1.29)** 
Noncore rural 0.94 (0.68-1.29) 1.06 (0.91-1.24) 
Complexity Level of the parent 
station 
  
 1a (Highest) Ref Ref 
 1b   1.01 (0.82-1.24) 1.00 (0.88-1.14) 
 1c 0.99 (0.83-1.18) 0.94 (0.84-1.06) 
 2 0.99 (0.82-1.18) 0.88 (0.77-1.00)* 
 3 (Least Complex) 1.06 (0.89-1.28) 0.92 (0.80-1.06) 
Bed Size of CLC   
 >120 beds Ref Ref 
 60-120 beds 1.05 (0.90-1.22) 1.03 (0.92-1.16) 
 <60 beds 1.06 (0.91-1.23) 1.03 (0.93-1.14) 
MD turnover rate   
Quartile 1 Ref Ref 
Quartile 2 1.13 (0.98-1.31) 1.01 (0.93-1.10) 
Quartile 3 1.11 (0.96-1.30) 0.99 (0.90-1.09) 
Quartile 4 1.16 (1.00-1.36) 1.00 (0.92-1.08) 
Nurse turnover rate   
Quartile 1 Ref Ref 
Quartile 2 1.07 (0.91-1.25) 1.08 (0.98-1.18) 
Quartile 3 1.08 (0.92-1.27) 1.10 (0.99-1.23) 
Quartile 4 1.05 (0.89-1.22) 1.10 (0.98-1.24) 
Pharmacist turnover rate   
Quartile 1 Ref Ref 
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Quartile 2 1.08 (0.96-1.21) 0.99 (0.90-1.09) 
Quartile 3 0.98 (0.87-1.11) 0.95 (0.86-1.05) 
Quartile 4 1.07 (0.94-1.21) 1.05 (0.96-1.15) 
Practical nurse turnover   
Quartile 1 Ref Ref 
Quartile 2 1.02 (0.87-1.20) 0.95 (0.87-1.04) 
Quartile 3 1.11 (0.95-1.30) 0.99 (0.91-1.08) 
Quartile 4 1.02 (0.87-1.20) 1.01 (0.91-1.11) 
Psychology Turnover   
Quartile 1 Ref Ref 
Quartile 2 0.89 (0.78-1.01) 0.97 (0.88-1.07) 
Quartile 3 0.97 (0.86-1.09) 1.01 (0.93-1.10) 
Quartile 4 1.00 (0.89-1.13) 1.03 (0.94-1.14) 
Medications prescribed (which may 
impact Aspirin Rx) 
  
Anti-platelet agents 2.59 (2.40-2.80)** 1.92 (1.77-2.09)** 
Anti-thrombotic agents 1.62 (1.50-1.76)** 1.35 (1.25-1.46)** 
H2RAs 1.34 (1.23-1.46)** 1.27 (1.17-1.38)** 
PPIs 1.28 (1.21-1.36)** 1.23 (1.17-1.29)** 
NSAIDs 1.18 (1.04-1.34)** 1.15 (1.01-1.31)* 
*p<0.05, **p<0.01 
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Figure 3: Factor Predicting Higher Odds of Aspirin Receipt 
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Figure 4: Factor Predicting Lower Odds of Aspirin Receipt 
3.4 Demographics of Sample Qualifying for Discontinuation 
A total of 13,844 residents received aspirin in the first week of the CLC stay and had at 
least 14 days of available follow-up in the CLC, and thus were included in the analysis of aspirin 
discontinuation. The sub-group was very similar to the overall sample, in that a majority of 
residents were 75 years of age (72%), male (99%), married (52%), non-Hispanic white (80%), 
and presented from an acute hospital setting prior to CLC admission (72.1%). The most common 
comorbidities included hypertension (94%), hyperlipidemia (70%), diabetes (54%), and 
congestive heart failure (53%); all comorbidities were slightly more prevalent in this subgroup 
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compared to the overall cohort. Comorbidities were common, with 40% of the population having 
more than five Elixhauser comorbidities. Markers of poor prognosis were common, including 
recent weight loss (40%), leaving food uneaten (40%), and cancer (34%). A majority of residents 
had no aggressive behavior (82%) but did have pain on admission (69%), and 50% had a history 
of falls, hip fractures or other fractures in the 180 days prior to admission. Co-administration of 
aspirin and antithrombotic therapy (51%) and proton pump inhibitors (53%) were common in this 
subgroup of initial aspirin users. Please refer to table 7 for full review of baseline characteristics 
in initial aspirin users.  
 
Table 7: Baseline Characteristics of the Cohort Qualifying for Discontinuation of Aspirin 
 Discontinuation Cohort 
(N= 13,844) 
Limited prognosis or 
hospice Indicator 
(N=4,092) 
No Limited Prognosis 
or Hospice Use 
Indicator 
(N=9.752) 
Demographics n (%)   
Age at admission**    
   65-74 3,839 (27.7) 1,030 (25.2) 2,809 (28.8) 
   75-84 5,260 (38.0) 1,557 (38.1) 3,703 (38.0) 
   ≥85 4,745 (34.3) 1,505 (36.8) 3,240 (33.2) 
Sex**    
   Male 13,686 (98.9) 4,020 (98.2) 9,666 (99.1) 
   Female 158 (1.1) 72 (1.8) 86 (0.9) 
Race/ethnicity*    
   White 11,121 (80.3) 3,323 (81.2) 7,798 (80.0) 
   Black 1,926 (13.9) 513 (12.5) 1,413 (14.5) 
   Hispanic 547 (4.0) 178 (4.4) 369 (3.8) 
   Other  250 (1.8) 78 (1.9) 172 (1.8) 
Marital status    
   Married 7,199 (52.0) 2,272 (55.5) 4,927 (50.5) 
   Not married 6,645 (48.0) 1,820 (44.5) 4,825 (49.5) 
    
Environment of Care Factors    
Fiscal year of admission    
   2009 1,864 (13.5) 514 (12.6) 1,350 (13.8) 
   2010 1,852 (13.4) 572 (14.0) 1,280 (13.1) 
   2011 1,960 (14.2) 596 (14.6) 1,364 (14.0) 
   2012 1,986 (14.4) 578 (14.1) 1,408 (14.4) 
   2013 2,124 (15.2) 612 (15.0) 1,512 (15.5) 
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   2014 2,118 (15.3) 654 (16.0) 1,464 (15.0) 
   2015 1,940 (14.0) 566 (13.8) 1,374 (14.1) 
Living arrangement before 
admission** 
   
   Acute hospital 25,143 (67.7) 2,889 (70.6) 7,090 (72.7) 
   Community  9,074 (24.4) 826 (20.2) 1,918 (19.7) 
   Nursing home 1,932 (5.2) 251 (6.1) 537 (5.5) 
   Other 1,014 (2.7) 126 (3.1) 207 (2.1) 
Hospitalization in 90 days prior to 
admission** 
21,728 (58.5) 2,584 (63.2) 5,772 (59.2) 
Next of kin relationship to the 
Veteran** 
   
   Spouse 15,031 (40.4) 1,506 (36.8) 3,909 (40.1) 
   Child 15,296 (41.1) 1,799 (44.0) 3,940 (40.4) 
   Sibling 3,290 (8.9) 362 (8.9) 889 (9.1) 
   Other relative 1,594 (4.3) 192 (4.7) 421 (4.3) 
Friend or other specified   
person of unknown relation 
1,939 (5.2) 233 (5.7) 593 (6.1) 
Distance from next of kin ZIP code 
centroid to the CLC** 
   
 Quartile 1  9,979 (72.1) 1,176 (28.7) 2,285 (23.4) 
 Quartile 2  2,744 (19.8) 1,069 (26.1) 2,392 (24.5) 
 Quartile 3  788 (97.6) 997 (24.4) 2,464 (25.3) 
 Quartile 4  333 (2.4) 850 (20.8) 2,611 (26.8) 
    
Cardiovascular Risk Factors    
Number of qualifying conditions 
(CAD, stroke/TIA)** 
   
1 10.451 (75.5) 3,270 (79.9) 7,181 (73.6) 
2 3,393 (24.5) 822 (20.1) 2,571 (26.4) 
Diabetes** 7,466 (53.9) 1,933 (47.2) 5,533 (56.7) 
Congestive heart failure* 7,317 (52.9) 2,228 (54.5) 5,089 (52.2) 
Hypertension** 12,982 (93.8) 3,777 (92.3) 9,205 (94.4) 
Hyperlipidemia** 9,742 (70.4) 2,792 (68.2) 6,950 (71.3) 
Venous thromboembolism  1,643 (11.9) 509 (12.4) 1,134 (11.6) 
Atrial fibrillation last year 2,648 (19.1) 816 (19.9) 1,832 (18.8) 
Recent Myocardial Infarction in the 
last year** 
1,161 (8.4) 403 (9.9) 758 (7.8) 
Recent Stroke in the last year** 3,733 (27.0) 897 (21.9) 2,836 (29.1) 
Current Smoker    
No 12,611 (91.1) 3,693 (90.3) 8,918 (91.5) 
Yes 1,233 (8.9) 399 (9.8) 834 (8.6) 
Body Mass Index (kg/m2)**    
 Normal or healthy weight 
(18.5 to <25.0) 
5,968 (43.1) 1,962 (48.0) 4,006 (41.1) 
 Underweight (<18.5) 1,107 (8.0) 472 (11.5) 635 (6.5) 
 Overweight (25.0 to <30.0) 3,970 (28.7) 1,084 (26.5) 2,886 (29.6) 
 Obese (≥30) 2,799 (20.2) 574 (14.0) 2,225 (22.8) 
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Markers of Poor Prognosis    
Advanced dementia** 4,211 (30.4) 1,075 (26.3) 3,136 (32.2) 
Documentation of limited prognosis 
or hospice use at admission 
4,094 (29.6)   
Number of Elixhauser conditions**    
0-1 1,019 (7.4) 221 (5.4) 798 (8.2) 
2-3 3,144 (22.7) 846 (20.7) 2,298 (23.6) 
4-5 4,145 (29.9) 1,264 (30.9) 2,881 (29.5) 
>5 5,536 (40.0) 1,761 (43.0) 3,775 (38.7) 
Recent weight loss** 5,555 (40.1) 1,568 (38.3) 3,987 
Leaves food uneaten** 5,478 (39.6) 2,025 (49.5) 3,453 (35.4) 
Renal failure** 2,830 (20.4) 681 (16.6) 2,149 (22.0) 
Dehydration 138 (1.0) 43 (1.1) 95 (1.0) 
Acute change in mental status** 1,365 (9.9) 496 (12.1) 869 (8.9) 
Shortness of breath** 5,586 (40.4) 1,883 (46.0) 3,703 (38.0) 
Cancer** 4,633 (33.5) 1,740 (42.5) 2,893 (29.7) 
Activities of Daily Living (ADL) 
score** 
   
0 - <1 1,438 (10.4) 464 (11.3) 974 (10.0) 
1 to <2 3,218 (23.2) 733 (17.9) 2,485 (25.5) 
2 to <3 4,714 (34.1) 1,203 (29.4) 3,511 (36.0) 
3 to <4 3,185 (23.0) 1,127 (27.5) 2,085 (21.1) 
4 1,289 (9.3) 565 (13.8) 724 (7.4) 
Aggressive Behavior**    
 None  11,405 (82.4) 3,469 (84.8) 7,936 (81.4) 
 Moderate  1,552 (11.2) 378 (9.2) 1,174 (12.0) 
 Severe  669 (4.8) 193 (4.7) 476 (4.9) 
 Very severe  218 (1.6) 52 (1.3) 166 (1.7) 
IV feeding tube in place** 1,282 (9.3) 275 (6.7) 1,007 (10.3) 
On Mechanical Diet** 5,643 (40.8) 1,869 (45.7) 3,774 (38.7) 
Swallowing Problems**  2,538 (18.3) 849 (20.8) 1,689 (17.3) 
Presence of any pain (n, % yes)**    
Yes 9,563 (69.1) 3,005 (73.4) 6,558 (67.3) 
No 4,281 (30.9) 1,087 (26.6) 3,194 (32.8) 
History of falls, hip fracture, and 
other fractures in past 180 days** 
   
Yes  6,870 (49.6) 1,929 (47.1) 4,941 (50.7) 
No  6,974 (50.4) 2,163 (52.9) 4,811 (49.3) 
   
Facility Factors   
US Census region of the CLC**    
 Northeast 2,355 (17.0) 821 (20.1) 1,534 (15.7) 
 Midwest 4,528 (32.7) 1,070 (26.2) 3,458 (35.5) 
 South 4,604 (33.3) 1,466 (35.8) 3,138(32.2) 
 West 2,357 (17.0) 735 (18.0) 1,622 (16.6) 
Urban Influence Code for the CLC**    
Large metro 6,201 (44.8) 1,648 (40.3) 4,553 (46.7) 
Small metro 5,078 (36.7) 1,593 (38.9) 3,485 (35.7) 
Micropolitan 1,110 (8.0) 390 (9.5) 720 (7.4) 
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Noncore rural 1,455 (10.5) 461 (11.3) 994 (10.2) 
Complexity Level of the parent 
station** 
   
1a (Highest) 5, 236 (37.8) 1,430 (35.0) 3,806 (39.0) 
1b   1,583 (11.4) 452 (11.1) 1,131 (11.6) 
1c 2,517 (18.2) 829 (20.3) 1,688 (17.3) 
2 1,949 (14.1) 612 (15.0) 1,337 (13.7) 
3 (Least Complex) 2,559 (18.5) 769 (18.8) 1,790 (18.4) 
Bed Size of CLC**    
 <60 beds 2,034 (14.7) 773 (18.9) 1,261 (12.9) 
 60-120 beds 4,934 (35.6) 1,399 (34.2) 3,535 (36.3) 
 >/= 120 beds 6,876 (49.7) 1,920 (46.9) 4,956 (50.8) 
Physician turnover rate**    
Quartile 1 3,479 (25.1) 1,095 (26.8) 2,384 (24.5) 
Quartile 2 3,492 (25.2) 958 (23.4) 2,534 (26.0) 
Quartile 3 3,463 (25.0) 1,066 (26.1) 2,397 (24.6) 
Quartile 4 3,410 (24.6) 973 (23.8) 2,437 (25.0) 
Nurse turnover rate    
Quartile 1 3,532 (25.5) 1,007 (24.6) 2,525 (25.9) 
Quartile 2 3,422 (24.7) 987 (24.1) 2,435 (25.0) 
Quartile 3 3,447 (24.9) 1,036 (25.3) 2,411 (24.7) 
Quartile 4 3,443 (24.9) 1,062 (26.0) 2,381 (24.4) 
Pharmacist turnover rate**    
Quartile 1 3,476 (25.1) 1,158 (28.3) 2,318 (23.8) 
Quartile 2 3,516 (25.4) 898 (22.0) 2,618 (26.9) 
Quartile 3 3,397 (24.5) 957 (23.4) 2,440 (25.0) 
Quartile 4 3,455 (25.0) 1,079 (26.4) 2,376 (24.4) 
Practical nurse turnover**    
Quartile 1 3,477 (25.1) 1,087 (26.6) 2,390 (24.5) 
Quartile 2 3,461 (25.0) 998 (24.4) 2,463 (25.3) 
Quartile 3 3,467 (25.0) 962 (23.5) 2,505 (25.7) 
Quartile 4 3,439 (24.8) 1,045 (25.5) 2,394 (24.6) 
Psychology Turnover*    
Quartile 1 3,505 (25.3) 1,033 (25.2) 2,472 (25.4) 
Quartile 2 3,435 (24.8) 1,046 (25.6) 2,389 (24.5) 
Quartile 3 3,493 (25.2) 965 (23.6) 2,528 (25.9) 
Quartile 4 3,411 (24.6) 1,048 (25.6) 2,363 (24.2) 
Medications Prescribed Which May Impact Aspirin 
Prescribing 
  
Anti-platelet** 2,558 (18.5) 666 (16.3) 1,892 (19.4) 
Anti-thrombotic 
Agents** 
7,057 (51.0) 1,707 (41.7) 5,250 (54.9) 
H2-Receptor 
Antagonists* 
1,547 (11.2) 421 (10.3) 1,126 (11.6) 
Proton Pump Inhibitors 7,290 (52.7) 2,119 (51.8) 5,171 (53.0) 
NSAIDs** 514 (3.7) 124 (3.0) 390 (4.0) 
*p<0.05, **p<0.01 for differences by limited prognosis or hospice use stratification 
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3.5 Incidence and Factors Predicting Discontinuation of Aspirin for Secondary Prevention 
of Cardiovascular Disease  
The cumulative incidence of aspirin discontinuation by day 91 of the CLC stay in this 
cohort was 33% (95% CI, 0.32-0.34). See figure 5 below for the cumulative incidence of aspirin 
discontinuation from day 0 to 91.  
 Results of the bivariable and multivariable competing risk models are shown in Table 8. 
As the goal of this analysis is to identify factors significantly associated with aspirin 
discontinuation in the first 91 days of CLC admission, independent of all other factors, we 
highlight the results from the fully adjusted multivariable model here. 
Demographics factors associated with lower hazards of discontinuation include being 75-
84 years of age (aSDHR 0.91, 95% CI 0.83-1.00), and being greater than 85 years old (aOR 0.89, 
95% CI 0.80-0.99) versus 65-74 years.  Hispanic ethnicity (aSDHR 1.43, 95% CI 1.13-1.81) and 
other non-White, non-Hispanic race/ethnicity (aSDHR 1.30, 95% CI 1.03-1.64) versus White, non-
Hispanic race/ethnicity was associated with higher hazards of discontinuation.  
Amongst environment of care factors associated with discontinuation, treatment in fiscal 
year 2012 was associated with higher hazards of discontinuation (aSDHR 1.23, 95% CI 1.04-1.46) 
versus year 2009. Factors predicting lower hazards of discontinuation of aspirin included those 
coming from the community (aSDHR 0.73, 95% CI 0.65-0.83) or from a nursing home (aSDHR 
0.66, 95% CI 0.55-0.80) compared to coming from an acute hospital.  
A few cardiovascular risk factors were associated with lower hazards of aspirin 
discontinuation, including diabetes (aSDHR 0.87, 95% CI 0.81-0.93) and having had an MI in the 
year prior to CLC admission (aSDHR 0.76, 95% CI 0.65-0.89). 
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A number of factors indicating limited prognosis were implicated in aspirin 
discontinuation. Having 2-3 Elixhuaser comorbidities (aSDHR 1.26, 95% CI 1.08-1.47), 4-5 
Elizhauser comorbidities (aSDHR 1.20, 95% CI 1.02-1.41), and > 5 Elixhauser comorbidities 
(aSDHR 1.32, 95% CI 1.11-1.57) versus 0-1 comorbidities was associated with higher hazards of 
aspirin discontinuation. Those with a documented limited prognosis or hospice use at admission 
had the highest hazards of aspirin discontinuation (aSDHR 1.89, 95% CI 1.67-2.14). Other factors 
associated with higher hazards of discontinuation include: recent weight loss (aSDHR 1.11, 95% 
CI 1.03-1.19), leaving food uneaten (aSDHR 1.14, 95% CI 1.05-1.23), renal failure (aSDHR 1.16, 
95% CI, 1.04-1.29), cancer (aSDHR 1.13, 95% CI 1.04-1.22), IV feeding tube requirement 
(aSDHR 1.21, 95% CI 1.06-1.38), those with dependence on 3 to < 4 ADLs (aSDHR 1.24, 95% 
CI 1.07-1.45), and all 4 ADLs versus those dependent on <1 ADL (aSDHR 1.37, 95% CI 1.15-
1.63).   
Amongst facility level factors, having a bed size at the CLC of < 60 versus ≥ 120 (aSDHR 
0.81, 95% CI 0.68-0.97), having a nursing turnover rate in quartile 4 versus quartile 1 (aSDHR 
0.80, 95% CI 0.66-0.98) and having a psychology turnover rate in quartile 4 versus quartile 1 
(aSDHR 0.84, 95% CI 0.72-0.98) are associated with lower hazards of aspirin discontinuation. 
Having practical nursing turnover rates in quartile 3 versus 1 (aSDHR 1.18, 95% CI 1.02-1.36) 
and being cared for in a CLC in the South versus Northeast (aSDHR 1.24, 95% CI 1.01-1.52) was 
associated with higher hazards of discontinuation.  
No medications which impact the risk of bleeding when combined with aspirin were 
associated with aspirin discontinuation.  
In stratified analyses, in those with hospice or limited prognosis documented at admission, 
the following variables were no longer significantly associated with aspirin discontinuation: the 
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age category of 75-84 years, other or Hispanic race/ethnicity, recent MI, recent weight loss, cancer, 
IV feeding tube requirement, ADL short form score of 4 versus 0 to <1, being cared for in the 
South vs. Northeast, less than 60 beds versus > 120 beds in the CLC facility, nursing turnover rate 
quartile 4, psychology turnover rate quartile 4. However, in all cases the direction and magnitude 
of the aSDHR was similar to that observed in the non-stratified analyses. Variables which became 
significant in the limited prognosis and hospice use group, which were not previously associated 
with discontinuation in the adjusted model included: being care for in fiscal year 2015 versus 2009 
(aSDHR 1.37, 95% CI 1.01-1.85), having a child as a NOK versus a spouse (aSDHR 1.21, 95% 
CI 1.02-1.44), congestive heart failure (aSDHR 0.88, 95% CI 0.78-0.99),  being overweight versus 
normal weight (aSDHR 1.17, 95% CI 1.03-1.34), shortness of breath (aSDHR 0.86, 95% CI 0.76-
0.97), ADL short form score of 2 to < 3 (aSDHR 1.27, 95% CI 1.00-1.61), being cared for in the 
West U.S. region versus the Northeast (aSDHR 1.38, 95% CI 1.02-1.88), facility complexity levels 
1b (aSDHR 0.70, 95% CI 0.53-0.93), and 1c (aSDHR 0.75, 95% CI 0.57-0.99) versus complexity 
level 1a, quartiles 3 (aSDHR 1.25, 95% CI 1.03-1.50) and quartile 4 (aSDHR 1.23, 95% CI 1.01-
1.50) of the pharmacist turnover rates categories compared to quartile 1, quartile 2 versus 1 of the 
practical nurse turnover rates (aSDHR 1.26, 95% CI 1.01-1.56), quartile 2 versus 1 of the  
psychology turnover category (aSDHR 1.26, 95% CI 1.02-1.56), and proton pump inhibitors 
(aSDHR 1.15, 95% CI 1.02-1.30). 
Amongst those not in the limited prognosis or hospice use group, the following variables 
were no longer significantly associated with aspirin discontinuation, age categories  75-84 and ≥ 
85 years, other race or ethnicity, admission during fiscal year 2012, any of the Elixhauser 
comorbidity categories, leaving food uneaten, ADL short form scores of 3 to <4 and 4, residing in 
a CLC in the South, and practical nurse turnover rates in quartile 3. Again, in all cases the direction 
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and magnitude of the aSDHR was similar to that observed in the non-stratified analyses. The 
following variables were significant in the group without limited prognosis or hospice use at 
admission, which were not previously significant in the adjusted model:  congestive heart failure 
(aSDHR 1.13, 95% CI 1.01-1.26), venous thromboembolism (aSDHR 1.23, 95% CI 1.07-1.41), 
current smoking status (aSDHR 1.21, 95% CI 1.01-1.45), shortness of breath (aSDHR 1.12, 95% 
CI 1.00-1.25, psychology turnover rates in quartile 3 versus quartile 1 (aSDHR 0.80, 95% CI 0.68-
0.93), and the use of anti-thrombotic agents (aSDHR 1.13, 95% CI 1.01-1.26).  
 
 
Figure 5: Cumulative Incidence of Discontinuation of Aspirin for Secondary Prevention of Cardiovascular 
Disease 
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Table 8: Univariable and Adjusted Subdistribution Hazard Ratios (SDHRs) for the Hazard of 
Discontinuation of Aspirin, Competing Risk Survival Analysis 
 Unadjusted SDHR 
N=13,844 
Adjusted SDHR 
N=13,844 
Limited Prognosis 
Indicator 
Documented 
N=4,092 
No Indication of 
Limited Prognosis 
Documented 
N=9,752 
Demographics SDHR (95% CI) aSDHR (95% CI) aSDHR (95% CI) aSDHR (95% CI) 
Age at admission     
 65-74 Ref Ref Ref Ref 
 75-84 1.04 (0.92-1.17) 0.91 (0.83-1.00)* 0.87 (0.75-1.02) 0.95 (0.84-1.07) 
 ≥85 1.05 (0.93-1.18) 0.89 (0.80-0.99)* 0.80 (0.69-0.94)** 0.99 (0.87-1.13) 
Sex     
 Female 1.43 (1.02-2.02)* 0.98 (0.68-1.40) 1.02 (0.68-1.51) 0.93 (0.53-1.64) 
Race/ethnicity     
   White Ref Ref Ref Ref 
   Black 1.03 (0.89-1.20) 1.00 (0.91-1.11) 1.17 (0.98-1.41) 0.92 (0.80-1.05) 
   Hispanic 1.53 (1.12-2.09)** 1.43 (1.13-1.81)** 1.36 (0.97-1.91) 1.51 (1.16-1.98)** 
 Other  1.23 (0.85-1.77) 1.30 (1.03-1.64)* 1.30 (0.91-1.87) 1.30 (0.97-1.73) 
Marital status     
   Married 0.98 (0.89-1.08) 1.08 (0.96-1.21) 1.13 (0.95-1.34) 1.05 (0.90-1.23) 
     
Environment of 
Care Factors 
    
Fiscal year of 
admission 
    
   2009 Ref Ref Ref Ref 
   2010 1.07 (0.91-1.26) 1.04 (0.91-1.18) 1.17 (0.95-1.43) 1.02 (0.84-1.23) 
   2011 1.11 (0.91-1.36) 0.95 (0.83-1.09) 1.16 (0.92-1.47) 0.86 (0.73-1.03) 
   2012 1.18 (0.96-1.45) 1.23 (1.04-1.46)** 1.60 (1.22-2.08)** 1.06 (0.88-1.28) 
   2013 0.95 (0.76-1.18) 1.07 (0.90-1.27) 1.25 (0.96-1.63) 0.97 (0.80-1.18) 
   2014 1.05 (0.85-1.31) 1.15 (0.96-1.37) 1.24 (0.93-1.66) 1.09 (0.88-1.34) 
   2015 1.17 (0.96-1.43) 1.17 (0.97-1.41) 1.37 (1.01-1.85)* 1.07 (0.87-1.33) 
Living 
arrangement 
before admission 
    
Acute hospital Ref Ref Ref Ref 
Community 0.56 (0.47-0.68)** 0.73 (0.65-0.83)** 0.69 (0.58-0.82)** 0.80 (0.69-0.93)** 
Nursing home 0.54 (0.39-0.73)** 0.66 (0.55-0.80)** 0.70 (0.52-0.94)* 0.65 (0.49-0.86)** 
Other 0.63 (0.44-0.91)* 0.83 (0.66-1.04) 0.75 (0.55-1.02) 0.90 (0.62-1.32) 
Hospitalization in 
90 days prior to 
admission 
1.09 (0.98-1.21) 1.03 (0.94-1.11) 1.05 (0.93-1.19) 0.99 (0.90-1.10) 
Next of kin 
relationship to the 
Veteran¥ 
    
Spouse Ref Ref Ref Ref 
Child 1.06 (0.95-1.18) 1.11 (0.99-1.25) 1.21 (1.02-1.44)* 1.04 (0.88-1.22) 
Sibling 0.90 (0.76-1.08) 0.98 (0.84-1.16) 0.92 (0.71-1.19) 1.00 (0.81-1.24) 
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Other relative 1.12 (0.89-1.41) 1.04 (0.84-1.28) 1.18 (0.91-1.53) 0.97 (0.70-1.35) 
Friend or other 
specified person 
of unknown 
relation 
0.94 (0.75-1.18) 1.04 (0.85-1.27) 1.09 (0.82-1.46) 0.98 (0.76-1.26) 
Distance from next 
of kin ZIP code 
centroid to the 
CLC¥ 
    
Quartile 1   Ref Ref Ref Ref 
Quartile 2   1.00 (0.86-1.15) 1.02 (0.93-1.12) 1.06 (0.93-1.22) 0.97 (0.85-1.09) 
Quartile 3  0.97 (0.82-1.14) 1.02 (0.93-1.12) 1.00 (0.86-1.18) 1.03 (0.91-1.17) 
Quartile 4  0.86 (0.74-1.01) 0.94 (0.83-1.06) 0.97 (0.83-1.15) 0.90 (0.78-1.04) 
     
Cardiovascular 
Risk Factors 
    
Number of 
qualifying 
conditions (CAD, 
stroke/TIA, 
and/or diabetes) 
    
1 Ref Ref Ref Ref 
2 0.79 (0.71-0.88)** 0.91 (0.81-1.02) 0.89 (0.74-1.07) 0.92 (0.79-1.06) 
Diabetes 0.80 (0.73-0.87)** 0.87 (0.81-0.93)** 0.87 (0.78-0.97)* 0.86 (0.77-0.95)** 
Congestive heart 
failure 
1.06 (0.95-1.17) 1.01 (0.93-1.10) 0.88 (0.78-0.99)* 1.13 (1.01-1.26)* 
Hypertension 0.90 (0.73-1.12) 0.98 (0.83-1.16) 1.14 (0.90-1.43) 0.85 (0.69-1.05) 
Hyperlipidemia 0.90 (0.81-0.99)* 0.97 (0.90-1.06) 0.99 (0.88-1.12) 0.95 (0.86-1.05) 
Venous 
Thromboembolis
m  
1.21 (1.06-1.39)** 1.10 (0.99-1.22) 0.95 (0.79-1.15) 1.23 (1.07-1.41)** 
Atrial Fibrillation  1.07 (0.95-1.21) 1.01 (0.92-1.11) 0.93 (0.81-1.05) 1.09 (0.94-1.27) 
Recent stroke  0.90 (0.79-1.03) 0.99 (0.88-1.12) 0.93 (0.77-1.11) 1.05 (0.89-1.23) 
Recent MI  0.87 (0.70-1.07) 0.76 (0.65-0.89)** 0.90 (0.73-1.12) 0.63 (0.51-0.77)** 
Current Smoker 0.95 (0.80-1.13) 1.08 (0.95-1.23) 0.98 (0.81-1.20) 1.21 (1.01-1.45)* 
Body Mass Index      
Normal or 
healthy weight 
(18.5 to <25.0) 
Ref Ref Ref Ref 
Underweight 
(<18.5) 
1.42 (1.20-1.69)** 1.10 (0.95-1.27) 1.05 (0.88-1.26) 1.14 (0.95-1.36) 
Overweight 
(25.0 to <30.0) 
0.95 (0.84-1.08) 1.09 (0.99-1.19) 1.17 (1.03-1.34)* 1.05 (0.92-1.19) 
Obese (≥30) 0.82 (0.69-0.96)* 1.04 (0.92-1.17) 1.10 (0.92-1.32) 0.98 (0.86-1.13) 
     
Factors indicating 
limited prognosis 
    
Documentation of 
limited prognosis 
3.37 (2.89-3.93)** 1.89 (1.67-2.14)**   
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or hospice use at 
admission 
Number of 
Elixhauser 
conditions 
    
0-1 Ref Ref Ref Ref 
2-3 1.51 (1.21-1.87)** 1.26 (1.08-1.47)** 1.38 (1.06-1.80)* 1.20 (0.95-1.52) 
4-5 1.52 (1.20-1.93)** 1.20 (1.02-1.41)* 1.40 (1.06-1.84)* 1.06 (0.85-1.32) 
>5 1.65 (1.29-2.11)** 1.32 (1.11-1.57)** 1.48 (1.12-1.96)** 1.20 (0.94-1.53) 
Advanced 
dementia 
1.00 (0.84-1.19) 1.00 (0.91-1.10) 1.14 (0.99-1.30) 0.91 (0.80-1.05) 
Recent weight loss 1.15 (1.04-1.28)** 1.11 (1.03-1.19)** 1.08 (0.96-1.21) 1.14 (1.02-1.27)* 
Leaves food 
uneaten 
1.64 (1.46-1.85)** 1.14 (1.05-1.23)** 1.17 (1.03-1.32)* 1.08 (0.96-1.21) 
Renal failure 0.96 (0.84-1.10) 1.16 (1.04-1.29)** 1.16 (1.00-1.36)* 1.16 (1.02-1.33)* 
Dehydration 1.19 (0.66-2.16) 1.06 (0.73-1.54) 1.20 (0.78-1.86) 0.94 (0.56-1.58) 
Acute change in 
mental status 
1.43 (1.20-1.72)** 1.12 (0.99-1.27) 1.06 (0.87-1.30) 1.15 (1.00-1.34) 
Shortness of 
breath  
 
1.09 (0.97-1.23) 0.98 (0.90-1.07) 0.86 (0.76-0.97)* 1.12 (1.00-1.25)* 
Cancer 1.16 (1.04-1.30)* 1.13 (1.04-1.22)** 1.04 (0.92-1.17) 1.18 (1.05-1.33)** 
Swallowing 
Problems 
1.44 (1.27-1.64)** 1.04 (0.94-1.15) 1.09 (0.95-1.24) 0.95 (0.83-1.08) 
IV feeding tube 1.14 (0.96-1.36) 1.21 (1.06-1.38)** 0.99 (0.80-1.24) 1.37 (1.15-1.62)** 
Mechanical diet  1.30 (1.18-1.43)** 1.03 (0.96-1.12) 1.03 (0.92-1.16) 1.03 (0.91-1.17) 
ADL score     
0 - <1 Ref Ref Ref Ref 
1 to <2 0.96 (0.79-1.17) 0.98 (0.84-1.13) 1.09 (0.88-1.35) 0.88 (0.73-1.05) 
2 to <3 1.20 (1.00-1.43)* 1.11 (0.95-1.29) 1.27 (1.00-1.61)* 0.95 (0.78-1.15) 
3 to <4 1.64 (1.36-1.97)** 1.24 (1.07-1.45)** 1.29 (1.02-1.63)* 1.11 (0.92-1.35) 
4 2.39 (1.92-2.98)** 1.37 (1.15-1.63)** 1.31 (1.00-1.73) 1.26 (0.99-1.60) 
Aggressive 
Behavior 
    
   None Ref Ref Ref Ref 
   Moderate  1.04 (0.88-1.24) 1.10 (0.99-1.22) 1.06 (0.89-1.27) 1.09 (0.94-1.26) 
   Severe  0.99 (0.76-1.27) 1.06 (0.90-1.24) 1.14 (0.91-1.43) 0.96 (0.75-1.23) 
   Very severe 0.77 (0.49-1.21) 1.08 (0.81-1.44) 0.96 (0.58-1.57) 1.20 (0.84-1.71) 
Presence of any 
pain  
1.33 (1.16-1.51)** 1.02 (0.94-1.10) 1.05 (0.93-1.18) 1.00 (0.89-1.10) 
History of falls, 
hip fracture, and 
other fractures in 
past 180 days  
0.94 (0.85-1.05) 1.01 (0.94-1.09) 1.02 (0.92-1.12) 1.00 (0.90-1.10) 
     
Facility Factors     
US Census region 
of the CLC 
    
Northeast Ref Ref Ref Ref 
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Midwest 1.02 (0.74-1.43) 1.10 (0.89-1.34) 1.16 (0.88-1.54) 1.02 (0.82-1.28) 
South 1.19 (0.82-1.74) 1.24 (1.01-1.52)* 1.20 (0.92-1.56) 1.19 (0.96-1.48) 
West 1.40 (0.95-2.07) 1.30 (1.00-1.70) 1.38 (1.02-1.88)* 1.25 (0.91-1.70) 
Urban Influence 
Code for the CLC 
    
   Large metro Ref Ref Ref Ref 
   Small metro 0.93 (0.74-1.18) 0.89 (0.77-1.03) 0.91 (0.75-1.10) 0.86 (0.74-1.01) 
   Micropolitan 1.50 (1.02-2.21)* 1.14 (0.92-1.41) 1.13 (0.77-1.66) 1.12 (0.92-1.35) 
   Noncore rural 0.86 (0.51-1.47) 0.84 (0.66-1.07) 0.88 (0.64-1.21) 0.79 (0.61-1.02) 
Complexity Level 
of the parent 
station 
    
   1a (Highest) Ref Ref Ref Ref 
   1b   0.77 (0.51-1.15) 0.88 (0.72-1.08) 0.70 (0.53-0.93)* 1.08 (0.86-1.34) 
   1c 0.78 (0.59-1.04) 0.85 (0.71-1.01) 0.75 (0.57-0.99)* 0.92 (0.77-1.09) 
   2 0.83 (0.64-1.08) 0.98 (0.81-1.19) 0.88 (0.66-1.19) 1.02 (0.81-1.29) 
   3 (Least 
Complex) 
0.71 (0.53-0.96) 1.01 (0.82-1.24) 0.88 (0.66-1.17) 1.12 (0.89-1.40) 
Bed Size of CLC     
   >120 beds Ref Ref Ref Ref 
   60-120 beds 0.78 (0.58-1.03) 0.87 (0.72-1.04) 0.87 (0.67-1.12) 0.89 (0.72-1.10) 
   <60 beds 0.67 (0.51-0.89)** 0.81 (0.68-0.97)* 0.83 (0.67-1.04) 0.82 (0.66-1.01)* 
MD turnover rate     
Quartile 1 Ref Ref Ref Ref 
Quartile 2 0.96 (0.75-1.22) 0.96 (0.82-1.11) 1.02 (0.82-1.26) 0.91 (0.77-1.08) 
Quartile 3 1.07 (0.85-1.35) 1.04 (0.90-1.21) 1.11 (0.89-1.39) 0.99 (0.84-1.17) 
Quartile 4 0.87 (0.70-1.07) 0.96 (0.83-1.10) 1.05 (0.82-1.35) 0.91 (0.77-1.08) 
Nurse turnover 
rate 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 0.98 (0.78-1.22) 0.91 (0.78-1.06) 0.92 (0.73-1.17) 0.92 (0.77-1.09) 
Quartile 3 0.88 (0.70-1.10) 0.84 (0.70-1.00) 0.85  (0.64-1.13) 0.84 (0.69-1.02) 
Quartile 4 0.89 (0.69-1.13) 0.80 (0.66-0.98)* 0.84 (0.63-1.11) 0.77 (0.61-0.97)* 
Pharmacist 
turnover rate 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 0.89 (0.72-1.09) 0.97 (0.83-1.13) 1.07 (0.87-1.32) 0.90 (0.75-1.09) 
Quartile 3 1.11 (0.93-1.33) 1.04 (0.91-1.19) 1.25 (1.03-1.50)* 0.90 (0.75-1.07) 
Quartile 4 0.99 (0.79-1.24) 1.07 (0.93-1.23) 1.23 (1.01-1.50)* 0.96 (0.81-1.14) 
Practical nurse 
turnover 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 1.21 (0.91-1.60) 1.13 (0.99-1.30) 1.26 (1.01-1.56)* 1.00 (0.85-1.19) 
Quartile 3 1.09 (0.85-1.39) 1.18 (1.02-1.36)* 1.23 (0.99-1.54)* 1.07 (0.90-1.26) 
Quartile 4 1.23 (0.93-1.62) 1.12 (0.95-1.33) 1.13 (0.89-1.45) 1.11 (0.93-1.33) 
Psychology 
Turnover 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 1.31 (1.06-1.61)* 1.11 (0.98-1.27) 1.26 (1.02-1.56)* 0.97 (0.83-1.13) 
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Quartile 3 0.98 (0.81-1.18) 0.94 (0.81-1.08) 1.11 (0.89-1.38) 0.80 (0.68-0.93)** 
Quartile 4 1.00 (0.81-1.22) 0.84 (0.72-0.98)* 0.91 (0.73-1.15) 0.75 (0.62-0.91)** 
Medications 
prescribed (which 
may impact 
Aspirin Rx) 
    
Anti-platelet 
agents 
0.82 (0.72-0.93)** 0.93 (0.84-1.03) 0.85 (0.72-1.01) 1.01 (0.88-1.15) 
Anti-
thrombotic 
agents 
1.14 (1.00-1.29)* 1.08 (0.98-1.19) 1.04 (0.91-1.19) 1.13 (1.01-1.26)* 
H2RAs 0.94 (0.80-1.12) 0.89 (0.78-1.00) 0.95 (0.79-1.15) 0.87 (0.73-1.04) 
PPIs 1.09 (0.98-1.21) 1.05 (0.98-1.13) 1.15 (1.02-1.30)* 0.97 (0.87-1.08) 
NSAIDs 1.04 (0.82-1.32) 0.96 (0.80-1.15) 1.03 (0.79-1.34) 0.92 (0.73-1.15) 
*p<0.05, **p<0.01, ¥ indicates the variable was imputed   
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Figure 7: Factors Predicting Lower Hazards of Aspirin Discontinuation 
3.6 Results of Sensitivity Analysis Using a 30-day Gap to Define Discontinuation 
A total of 9,430 residents qualified for the discontinuation sample for the sensitivity 
analysis, in that they received aspirin during the first week of the CLC stay and remained in the 
CLC for at least 30 days thereafter. Consistent with the discontinuation subgroup from the primary 
analysis, a majority of these residents were 75 years of age or older (71.7%), male (98.8%), non-
Hispanic white (79.9%), and married (52.7%). Most residents came from an acute hospital setting 
prior to CLC admission (71.2%). The most common comorbidities included diabetes (54.7%), 
congestive heart failure (52.1%), and hypertension (93.9%). Rates of concomitant medications and 
other indicators of poor prognosis were very similar to the primary analysis discontinuation 
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subgroup as well as the overall cohort for this study. See table 9 for the frequency of all covariates 
amongst the sensitivity analysis subgroup.  
The cumulative incidence of discontinuation by day 91 of the CLC stay in this sample was 
26% (CIF 0.26, 95% CI 0.25-0.27). See Figure 8 below for the cumulative incidence of 
discontinuation displayed over time (0-91 days).  
Results of the univariable and multivariable competing risk models are shown in Table 10. 
As the goal of this analysis is to identify factors significantly associated with aspirin 
discontinuation in the first 91 days of CLC admission, independent of all other factors, we 
highlight the results from the fully adjusted multivariable model here. 
Factors predicting hazards of discontinuation were consistent with the primary 
discontinuation analysis including: having other non-White/non-Hispanic race/ethnicity (aSDHR 
1.43, 95% CI 1.05-1.95), Hispanic ethnicity (aSDHR 1.59, 95% CI 1.19-2.14), admission from the 
community (aSDHR 0.83, 95% CI 0.72-0.96) or from a nursing home (aSDHR 0.69, 95% CI 0.55-
0.86) compared to an acute hospital, a diagnosis of diabetes (aSDHR 0.90, 95% CI 0.82-0.99), 
those with a recent MI in the year prior to CLC admission (aSDHR 0.78, 95% CI 0.62-0.98),  
having > 5 Elixhauser comorbidities (aSDHR 1.30, 95% CI 1.00-1.69) versus 0-1 comorbidities, 
documentation of limited prognosis or hospice use at admission (aSDHR 2.00, 95% CI 1.71-2.34), 
leaving food uneaten (aSDHR 1.24, 95% CI 1.13-1.37), cancer (aSDHR 1.13, 95% CI 1.03-1.24), 
IV feeding tube requirement (aSDHR 1.20, 95% CI 1.01-1.43), those with dependence on 3 to < 4 
ADLs (aSDHR 1.38, 95% CI 1.11-1.73), and all 4 ADLs versus those dependent on <1 ADL 
(aSDHR 1.65, 95% CI 1.28-2.13), nursing turnover rate in quartile 4 (aSDHR 0.80, 95% CI 0.65-
0.98), practical nursing turnover rates in  quartile 3 (aSDHR 1.28, 95% CI 1.08-1.51) versus 
quartile 1.  
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Factors no longer associated with discontinuation of aspirin in the sensitivity analysis 
included: being in the age category 75-84 years and being greater than 85 years versus 65-74 years, 
treatment in fiscal year 2012 versus year 2009, having 2-3 Elixhuaser comorbidities or 4-5 
Elizhauser comorbidities versus 0-1, recent weight loss, renal failure, being care for in the South 
versus the Northeast, bed sizes at the CLC of < 60 versus ≥ 120and a psychology turnover rate in 
quartile 4 versus quartile 1. The only factors which were significant in the sensitivity analysis but 
not significant in the primary analysis included: venous thromboembolism in the year prior 
(aSDHR 1.25, 95% CI 1.08-1.44) and having an ADL short form score of 2 to < 3 (aSDHR 1.38, 
95% CI 1.11-1.73). 
When stratified by receiving hospice or having a limited prognosis, the following variables 
were no longer significantly associated with aspirin discontinuation: hispanic ethnicity, other race 
and ethnicity category, coming from a nursing home versus an acute hospital, diagnosis of 
diabetes, venous thromboembolism is the last year, recent MI, cancer diagnosis, and IV feeding 
tube requirement. Variables which became significant in the limited prognosis and hospice use 
group, which were not previously associated with discontinuation in the adjusted sensitivity 
analysis model include: those in quartile 2 versus quartile 1 in distance from NOK (aSDHR 1.25, 
95% CI 1.05-1.48), congestive heart failure (aSDHR 0.85, 95% CI 0.72-1.00), Elixhauser 
comorbidity categories 2-3 (aSDHR 1.55, 95% CI 1.02-2.34), and 4-5 (aSDHR 1.59, 95% CI 1.08-
2.32) versus 0-1, renal failure (aSDHR 1.20, 95% CI 1.01-1.43),   ADL short form score of 1 to < 
2 (aSDHR 1.38, 95% CI 1.03-1.84) versus 0 to < 1, pharmacist turnover rate in quartile 3 versus 4 
(aSDHR 1.34, 95% CI 1.03-1.75), practical nurse turnover rate in quartile 2 versus 1 (aSDHR 1.41, 
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95% CI 1.07-1.87), and quartile 2 versus 1 of the  psychology turnover category (aSDHR 1.50, 
95% CI 1.14-1.97).  
Amongst those not in the limited prognosis or hospice use group, the following variables 
were no longer significantly associated with aspirin discontinuation: coming from the community 
or nursing home prior to admission versus an acute hospital, diabetes diagnosis, Elixhauser 
comorbidity category of > 5 versus 0-1, leaving food uneaten, cancer, all categories in the ADL 
short form scores, nursing turnover rate in quartile 4 versus 1, and quartile 3 of practical nurse 
turnover rates. The following variables were significant in the group without limited prognosis or 
hospice use at admission, which were not previously significant in the sensitivity analysis adjusted 
model: being cared for in fiscal year 2011 versus 2009 (aSDHR 0.77, 95% CI 0.62-0.96), current 
smoking status (aSDHR 1.37, 95% CI, 1.07-1.75), advanced dementia (aSDHR 0.82, 95% CI 0.68-
0.98), and quartiles 3 (aSDHR 0.78, 95% CI, 0.63-0.98) or quartile 4 (aSDHR 0.69, 95% CI, 0.53-
0.89) versus quartile 1 of the psychology turn over rate category.  
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Figure 8: Cumulative Incidence of Discontinuation: Sensitivity Analysis 
Table 9: Baseline Characteristics of the Cohort Qualifying for Discontinuation of Aspirin: Sensitivity 
Analysis 
 Discontinuation Cohort 
(N= 9.430) 
Limited Prognosis and 
Hospice Indicator 
(n=2,593) 
No Limited Prognosis 
or Hospice indicator 
(N=6,837) 
Demographics n (%) n (%) n (%) 
Age at admission**    
   65-74 2,670 (28.3) 638 (24.6) 2,032 (29.7) 
   75-84 3,581 (38.0) 976 (37.6) 2,605 (38.1) 
   ≥85 3,179 (33.7) 979 (37.8) 2,200 (32.2) 
Sex**    
   Male 9,321 (98.8) 2,548 (98.3) 6,773 (99.1) 
   Female 109 (1.2) 45 (1.7) 64 (0.9) 
Race/ethnicity*    
   White 7.533 (79.9) 2,114 (81.5) 5,419 (79.3) 
   Black 1,345 (14.3) 326 (12.6) 1,019 (14.9) 
   Hispanic 379 (4.0) 100 (3.9) 279 (4.1) 
   Other  173 (1.8) 53 (2.0) 120 (1.8) 
Marital status**    
   Married 4,972 (52.7) 1,448 (55.8) 3,524 (51.5) 
   Not married 4,458 (47.3) 1,145 (44.2) 3,313 (48.5) 
    
Environment of Care Factors    
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Fiscal year of admission    
   2009 1,313 (13.9) 327 (12.6) 986 (14.4) 
   2010 1,280 (13.6) 362 (14.0) 918 (13.4) 
   2011 1,368 (14.5) 386 (14.9) 982 (14.4) 
   2012 1,313 (13.9) 363 (14.0) 950 (13.9) 
   2013 1,441 (15.3) 386 (14.9) 1,055 (15.4) 
   2014 1,435 (15.2) 404 (15.6) 1,031 (15.1) 
   2015 1,280 (13.6) 365 (14.1) 915 (13.4) 
Living arrangement before 
admission** 
   
   Acute hospital 6,717 (71.2) 1,739 (67.1) 4,978 (72.8) 
   Community  1,799 (19.1) 581 (22.4) 1,218 (17.8) 
   Nursing home 651 (6.9) 184 (7.1) 467 (6.8) 
   Other 263 (2.8) 89 (3.4) 174 (2.5) 
Hospitalization in 90 days prior to 
admission* 
5,808 (61.6) 1,651 (63.7) 4,157 (60.8) 
Next of kin relationship to the 
Veteran* 
   
   Spouse 3,570 (37.9) 931 (35.9) 2,639 (38.6) 
   Child 3,964 (42.0) 1,157 (44.6) 2,807 (41.1) 
   Sibling 892 (9.5) 234 (9.0) 658 (9.6) 
   Other relative 434 (4.6) 124 (4.8) 310 (4.5) 
Friend or other specified   
person of unknown relation 
570 (6.0) 147 (5.7) 423 (6.2) 
Distance from next of kin ZIP code 
centroid to the CLC 
   
Quartile 1  2,360 (25.0) 755 (29.1) 1,605 (23.5) 
Quartile 2  2,355 (25.0) 677 (26.1) 1,678 (24.5) 
Quartile 3  2,358 (25.0) 627 (24.2) 1,731 (25.3) 
Quartile 4  2,357 (25.0) 534 (20.6) 1,823 (26.7) 
    
Cardiovascular Risk Factors    
Number of qualifying conditions 
(CAD, stroke/TIA)** 
   
1 7,009 (74.3) 2,051 (79.1) 4,958 (72.5) 
2 2,421 (25.7) 542 (20.9) 1,879 (27.5) 
Diabetes** 5,162 (54.7) 1,206 (46.5) 3,956 (57.9) 
Congestive heart failure 4,916 (52.1) 1,386 (53.5) 3,530 (51.6) 
Hypertension** 8.855 (93.9) 2,395 (92.4) 6,460 (94.5) 
Hyperlipidemia** 6,626 (70.3) 1,753 (67.6) 4,837 (71.3) 
Venous thromboembolism  1,144 (12.1) 309 (11.9) 835 (12.2) 
Atrial fibrillation last year 1,823 (19.3) 499 (19.2) 1,324 (19.4) 
Recent Myocardial Infarction in the 
last year** 
757 (8.0) 247 (9.5) 510 (7.5) 
Recent Stroke in the last year** 2,646 (28.1) 575 (22.2) 2,071 (30.3) 
Current Smoker*    
 No 8,589 (91.1) 2,331 (89.9) 6,258 (91.5) 
 Yes 841 (8.9) 262 (10.1) 579 (8.5) 
Body Mass Index (kg/m2)**    
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   Normal or healthy weight 
(18.5 to <25.0) 
4,065 (43.1) 1,239 (47.8) 2,826 (41.3) 
   Underweight (<18.5) 757 (8.0) 300 (11.6) 457 (6.7) 
   Overweight (25.0 to <30.0) 2,688 (28.5) 697 (26.9) 1,991 (29.1) 
   Obese (≥30) 1,920 (20.4) 357 (13.8) 1,563 (22.9) 
    
Markers of Poor Prognosis    
Advanced dementia** 2,906 (30.8) 652 (25.1) 2,254 (33.0) 
Documentation of limited prognosis 
or hospice use at admission 
2,593 (27.5) - - 
Number of Elixhauser conditions**    
0-1 694 (7.4) 144 (5.6) 550 (8.0) 
2-3 2,151 (22.8) 561 (21.6) 1,590 (23.3) 
4-5 2,771 (29.4) 781 (30.1) 1,990 (29.1) 
>5 3,814 (40.5) 1,107 (42.7) 2,707 (39.6) 
Recent weight loss** 3,804 (40.3) 979 (37.8) 2,825 (41.3) 
Leaves food uneaten** 3,619 (38.4) 1,176 (45.4) 2,443 (35.7) 
Renal failure** 1,941 (20.6) 424 (16.4) 1,517 (22.2) 
Dehydration 75 (0.8) 15 (0.6) 60 (0.9) 
Acute change in mental status 915 (9.7) 261 (10.1) 654 (9.6) 
Shortness of breath ** 3,574 (37.9) 1,148 (44.3) 2,426 (35.5) 
Cancer** 3,072 (32.6) 1,082 (41.7) 1,990 (29.1) 
Activities of Daily Living (ADL) 
score** 
   
0 - <1 956 (10.1) 325 (12.5) 631 (9.2) 
1 to <2 2,128 (22.6) 498 (19.2) 1,630 (23.8) 
2 to <3 3,286 (34.9) 796 (30.7) 2,490 (36.4) 
3 to <4 2,217 (23.5) 674 (26.0) 1,543 (22.6) 
4 843 (8.9) 300 (11.6) 543 (7.9) 
Aggressive Behavior**    
None  7,682 (81.5) 2,209 (85.2) 5,473 (80.1) 
Moderate  1,110 (11.8) 229 (8.8) 881 (12.9) 
Severe  477 (5.1) 122 (4.7) 355 (5.2) 
Very severe  161 (1.7) 33 (1.3) 128 (1.9) 
IV feeding tube in place** 924 (9.8) 164 (6.3) 760 (11.1) 
On Mechanical Diet** 3,856 (40.9) 1,156 (44.6) 2,700 (39.5) 
Swallowing Problems  1,736 (18.4) 505 (19.5) 1,231 (18.0) 
Presence of any pain (n, % yes)**    
Yes 6,398 (67.9) 1,847 (71.2) 4,551 (66.6) 
No 3,032 (32.2) 746 (28.8) 2,286 (33.4) 
History of falls, hip fracture, and 
other fractures in past 180 days** 
   
Yes  4,738 (50.3) 1,244 (48.0) 3,494 (51.1) 
No  4,692 (49.8) 1,349 (52.0) 3,343 (48.9) 
   
Facility Factors   
US Census region of the CLC**    
 Northeast 1,654 (17.5) 531 (20.5) 1,123 (16.4) 
 Midwest 2,946 (31.2) 686 (26.5) 2,260 (33.1) 
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 South 3,263 (34.6) 902 (34.8) 2,361 (34.5) 
 West 1,567 (16.6) 474 (18.3) 1,093 (16.0) 
Urban Influence Code for the 
CLC** 
   
 Large metro 4,180 (44.3) 1,039 (40.1) 3,141 (45.9) 
 Small metro 3,509 (37.2) 1,041 (40.2) 2,468 (36.1) 
 Micropolitan 684 (7.3) 214 (8.3) 470 (6.9) 
 Noncore rural 1,057 (11.2) 299 (11.5) 758 (11.1) 
Complexity Level of the parent 
station** 
   
1a (Highest) 3,474 (36.8) 818 (31.6) 2,656 (38.9) 
1b   1,071 (1.14) 307 (11.8) 764 (11.2) 
1c 1,707 (18.1) 518 (20.0) 1,189 (17.4) 
2 1,369 (14.5) 418 (16.1) 951 (13.9) 
3 (Least Complex) 1,809 (19.2) 532 (20.5) 1,277 (18.7) 
Bed Size of CLC**    
 <60 beds 1,288 (13.7) 470 (18.1) 818 (12.0) 
60-120 beds 3,175 (33.7) 868 (33.5) 2,307 (33.7) 
 >/= 120 beds 4,967 (52.7) 1,255 (48.4) 3,712 (54.3) 
Physician turnover rate    
Quartile 1 2,370 (25.1) 667 (25.7) 1,703 (24.9) 
Quartile 2 2,481 (26.3) 647 (25.0) 1,834 (26.8) 
Quartile 3 2,235 (23.7) 638 (24.6) 1,597 (23.4) 
Quartile 4 2,344 (24.9) 641 (24.7) 1,703 (24.9) 
Nurse turnover rate*    
Quartile 1 2,405 (25.5) 627 (24.2) 1,778 (26.0) 
Quartile 2 2,349 (24.9) 620 (23.9) 1,729 (25.3) 
Quartile 3 2,328 (24.7) 666 (25.7) 1,662 (24.3) 
Quartile 4 2,348 (24.9) 680 (26.2) 1,668 (24.4) 
Pharmacist turnover rate**    
Quartile 1 2,374 (25.2) 721 (27.8) 1,653 (24.2) 
Quartile 2 2,347 (24.9) 592 (22.8) 1,755 (25.7) 
Quartile 3 2,359 (25.0) 579 (22.3) 1,780 (26.0) 
Quartile 4 2,350 (24.9) 701 (27.0) 1,649 (24.1) 
Practical nurse turnover*    
Quartile 1 2,358 (25.0) 684 (26.4) 1,674 (24.5) 
Quartile 2 2,403 (25.5) 628 (24.2) 1,775 (26.0) 
Quartile 3 2,402 (25.5) 625 (24.1) 1,777 (26.0) 
Quartile 4 2,267 (24.0) 656 (25.3) 1,611 (23.6) 
Psychology Turnover**    
Quartile 1 2,367 (25.1) 674 (26.0) 1,693 (24.8) 
Quartile 2 2,351 (24.9) 625 (24.1) 1,726 (25.2) 
Quartile 3 2,355 (25.0) 596 (23.0) 1,759 (25.7) 
Quartile 4 2,357 (25.0) 698 (26.9) 1,659 (24.3) 
Medications Prescribed Which May Impact Aspirin 
Prescribing 
  
Anti-platelet* 1,749 (18.6) 435 (16.8) 1,314 (19.2) 
Anti-thrombotic 
Agents** 
4,729 (50.2) 1,026 (39.6) 3,703 (54.2) 
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H2- Receptor 
Antagonists 
1,020 (10.8) 259 (10.0) 761 (11.1) 
Proton Pump Inhibitors 4,962 (52.6) 1,329 (51.3) 3,633 (53.1) 
NSAIDs** 361 (3.8) 77 (3.0) 284 (4.2) 
*p<0.05, **p<0.01 for differences by limited prognosis or hospice use stratification 
 
Table 10: Univariable and Adjusted Subdistribution Hazard Ratios (SDHRs) for the Hazard of 
Discontinuation of Aspirin, Competing Risk Survival Analysis for Sensitivity Analysis 
 Unadjusted SDHR 
N=9,430 
Adjusted SDHR 
N=9,430 
Limited Prognosis 
Indicator 
Documented 
N=2,593 
No Indication of 
Limited Prognosis 
Documented 
N=6,837 
Demographics SDHR (95% CI) SDHR (95% CI) SDHR (95% CI) SDHR (95% CI) 
Age at admission     
   65-74 Ref Ref Ref Ref 
   75-84 1.09 (0.98-1.28) 0.94 (0.81-1.07) 0.96 (0.76-1.19) 0.92 (0.78-1.09) 
   ≥85 1.06 (0.90-1.25) 0.89 (0.77-1.04) 0.82 (0.65-1.03) 0.95 (0.80-1.14) 
Sex     
   Female 1.46 (0.90-2.36) 0.97 (0.61-1.56) 0.81 (0.47-1.40) 1.07 (0.54-2.13) 
Race/ethnicity     
   White Ref Ref Ref Ref 
   Black 1.05 (0.84-1.30) 1.05 (0.93-1.20) 1.12 (0.88-1.42) 1.02 (0.87-1.21) 
   Hispanic 1.58 (1.06-2.33)* 1.59 (1.19-2.14)** 1.40 (0.88-2.24) 1.70 (1.25-2.32)** 
   Other  1.13 (0.76-1.67) 1.43 (1.05-1.95)* 1.24 (0.76-.202) 1.55 (1.12-2.13)** 
Marital status     
   Married 1.00 (0.88-1.14) 1.04 (0.90-1.20) 1.07 (0.86-1.33) 1.01 (0.83-1.22) 
     
Environment of 
Care Factors 
    
Fiscal year of 
admission 
    
   2009 Ref Ref Ref Ref 
   2010 1.08 (0.85-1.37) 1.07 (0.89-1.27) 1.06 (0.78-1.44) 1.14 (0.92-1.40) 
   2011 0.96 (0.73-1.27) 0.88 (0.73-1.05) 1.10 (0.85-1.43) 0.77 (0.62-0.96)* 
   2012 1.13 (0.88-1.45) 1.20 (0.97-1.50) 1.27 (0.91-1.78) 1.21 (0.94-1.55) 
   2013 0.84 (0.61-1.15) 0.95 (0.75-1.21) 0.90 (0.65-1.26) 1.00 (0.76-1.32) 
   2014 0.99 (0.73-1.31) 1.12 (0.90-1.39) 1.13 (0.78-1.62) 1.12 (0.85-1.47) 
   2015 1.10 (0.85-1.43) 1.05 (0.84-1.31) 1.14 (0.80-1.63) 0.99 (0.75-1.31) 
Living 
arrangement 
before admission 
    
Acute hospital Ref Ref Ref Ref 
Community 0.64 (0.52-0.78)** 0.83 (0.72-0.96)* 0.74 (0.60-0.90)** 0.94 (0.78-1.13) 
Nursing home 0.47 (0.32-0.70)** 0.69 (0.55-0.86)** 0.71 (0.51-1.00) 0.69 (0.49-0.99)* 
Other 0.64 (0.38-1.08) 0.85 (0.63-1.14) 0.74 (0.51-1.09) 0.97 (0.61-1.54) 
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Hospitalization in 
90 days prior to 
admission 
1.12 (0.97-1.29) 
 
1.05 (0.93-1.18) 1.07 (0.89-1.29) 1.01 (0.88-1.16) 
Next of kin 
relationship to the 
Veteran¥ 
    
   Spouse Ref Ref Ref Ref 
   Child 1.05 (0.89-1.25) 1.09 (0.94-1.26) 1.27 (1.00-1.63) 0.96 (0.79-1.17) 
   Sibling 0.89 (0.70-1.14) 0.97 (0.78-1.20) 1.09 (0.78-1.54) 0.87 (0.66-1.13) 
   Other relative 1.05 (0.74-1.49) 0.89 (0.66-1.19) 0.99 (0.65-1.49) 0.88 (0.58-1.34) 
   Friend or 
other 
specified 
person of 
unknown 
relation 
0.79 (0.61-1.03) 0.92 (0.72-1.18) 1.11 (0.77-1.61) 0.77 (0.54-1.11) 
Distance from 
next of kin ZIP 
code centroid to 
the CLC¥ 
    
   Quartile 1   Ref Ref Ref Ref 
   Quartile 2   1.01 (0.84-1.22) 1.07 (0.97-1.20) 1.25 (1.05-1.48)* 0.94 (0.80-1.10) 
   Quartile 3  0.93 (0.74-1.16) 1.02 (0.89-1.16) 1.19 (0.97-1.46) 0.92 (0.78-1.08) 
   Quartile 4  0.85 (0.69-1.05) 0.91  (0.79-1.05) 0.93 (0.74-1.17) 0.89 (0.74-1.07) 
     
Cardiovascular 
Risk Factors 
    
Number of 
qualifying 
conditions (CAD, 
stroke/TIA, 
and/or diabetes) 
    
1 Ref Ref Ref Ref 
2 0.76 (0.67-0.90)** 0.98 (0.83-1.15) 0.80 (0.63-1.02) 1.07 (0.88-1.30) 
Diabetes 0.83 (0.73-0.95)** 0.90 (0.82-0.99)* 0.90 (0.78-1.03) 0.90 (0.79-1.02) 
Congestive heart 
failure 
1.07 (0.94-1.22) 1.00 (0.91-1.09) 0.85 (0.72-1.00)* 1.12 (0.98-1.29) 
Hypertension 0.88 (0.67-1.17) 0.94 (0.74-1.19) 1.16 (0.82-1.66) 0.78 (0.58-1.05) 
Hyperlipidemia 0.89 (0.79-1.02) 0.98 (0.87-1.10) 1.03 (0.88-1.21) 0.92 (0.79-1.07) 
Venous 
Thromboembolis
m  
1.38 (1.16-1.65)** 1.25 (1.08-1.44)** 1.16 (0.93-1.44) 1.35 (1.12-1.63)** 
Atrial Fibrillation  1.08 (0.90-1.30) 1.04 (0.92-1.17) 0.93 (0.75-1.14) 1.15 (0.97-1.38) 
Recent stroke  0.82 (0.69-0.98)* 0.90 (0.76-1.08) 0.92 (0.71-1.19) 0.89 (0.72-1.11) 
Recent MI  0.88 (0.65-1.19) 0.78 (0.62-0.98)* 0.91 (0.69-1.19) 0.63 (0.46-0.85)** 
Current Smoker 1.01 (0.80-1.30) 1.12 (0.94-1.33) 0.89 (0.69-1.15) 1.37 (1.07-1.75)* 
Body Mass Index      
Normal or 
healthy 
Ref Ref Ref Ref 
 75 
weight (18.5 
to <25.0) 
Underweight 
(<18.5) 
1.26 (1.00-1.59)* 1.05 (0.87-1.26) 0.94 (0.75-1.18) 1.17 (0.93-1.48) 
Overweight 
(25.0 to 
<30.0) 
0.90 (0.76-1.07) 1.03 (0.90-1.18) 1.08 (0.89-1.32) 1.01 (0.86-1.19) 
Obese (≥30) 0.86 (0.71-1.05) 1.09 (0.96-1.25) 1.13 (0.88-1.45) 1.05 (0.90-1.23) 
     
Factors indicating 
limited prognosis 
    
Documentation of 
limited prognosis 
or hospice use at 
admission 
3.40 (2.78-4.16)** 2.00 (1.71-2.34)**   
Number of 
Elixhauser 
conditions 
    
0-1 Ref Ref Ref Ref 
2-3 1.59 (1.14-2.21)** 1.25 (0.99-1.58) 1.55 (1.02-2.34)* 1.13 (0.82-1.55) 
4-5 1.57 (1.11-2.22)* 1.24 (0.98-1.57) 1.59 (1.08-2.32)* 1.09 (0.80-1.48) 
>5 1.68 (1.20-2.35)** 1.30 (1.00-1.69)* 1.62 (1.07-2.44)* 1.15 (0.82-1.60) 
Advanced 
dementia 
0.89 (0.73-1.10) 0.98 (0.88-1.11) 1.16 (0.98-1.37) 0.82 (0.68-0.98)* 
Recent weight loss 1.16 (0.99-1.35) 1.07 (0.96-1.19) 1.07 (0.91-1.27) 1.04 (0.90-1.21) 
Leaves food 
uneaten 
1.73 (1.49-2.00)** 1.24 (1.13-1.37)** 1.41 (1.20-1.64)** 1.08 (0.95-1.24) 
Renal failure 0.95 (0.79-1.15) 1.12 (1.00-1.26) 1.20 (1.01-1.43)* 1.04 (0.88-1.22) 
Dehydration 0.68 (0.25-1.83) 0.79 (0.44-1.43) 0.87 (0.33-2.30) 0.62 (0.28-1.40) 
Acute change in 
mental status 
1.28 (0.99-1.65) 1.15 (0.97-1.37) 1.16 (0.87-1.55) 1.12 (0.88-1.42) 
Shortness of 
breath  
 
1.18 (1.00-1.39)* 1.00 (0.88-1.13) 0.94 (0.80-1.11) 1.02 (0.86-1.21) 
Cancer 1.16 (0.99-1.36) 1.13 (1.03-1.24)** 1.13 (0.97-1.31) 1.07 (0.90-1.26) 
Swallowing 
Problems 
1.32 (1.12-1.55)** 1.07 (0.96-1.20) 1.13 (0.94-1.35) 0.98 (0.82-1.17) 
IV feeding tube 1.14 (0.91-1.42) 1.20 (1.01-1.43)* 1.01 (0.73-1.38) 1.36 (1.10-1.68)** 
Mechanical diet  1.20 (1.05-1.37)** 0.97 (0.87-1.08) 0.99 (0.85-1.16) 0.96 (0.81-1.13) 
ADL score     
0 - <1 Ref Ref Ref Ref 
1 to <2 1.00 (0.76-1.32) 1.15 (0.94-1.41) 1.38 (1.03-1.84)* 0.95  (0.73-1.24) 
2 to <3 1.17 (0.90-1.53) 1.38 (1.11-1.73)** 1.66 (1.23-2.24)** 1.09 (0.83-1.44) 
3 to <4 1.44 (1.08-1.91)* 1.40 (1.11-1.76)** 1.43 (1.02-2.00)* 1.17 (0.87-1.56) 
4 2.14 (1.53-2.99)** 1.65 (1.28-2.13)** 1.75 (1.17-2.63)* 1.30 (0.93-1.84) 
Aggressive 
Behavior 
    
None Ref Ref Ref Ref 
Moderate  0.82 (0.63-1.07) 0.92 (0.79-1.07) 0.89 (0.69-1.15) 0.92 (0.77-1.10) 
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Severe  1.03 (0.74-1.44) 1.08 (0.89-1.32) 1.16 (0.85-1.58) 0.99 (0.73-1.32) 
Very severe 0.59 (0.33-1.06) 0.86 (0.58-1.28) 0.68 (0.29-1.59) 1.00 (0.61-1.63) 
Presence of any 
pain  
1.33 (1.11-1.60)** 1.02 (0.91-1.13) 1.07 (0.90-1.26) 0.98 (0.84-1.14) 
History of falls, 
hip fracture, and 
other fractures in 
past 180 days  
0.94 (0.82-1.08) 1.02 (0.91-1.14) 0.99 (0.85-1.15) 1.04 (0.90-1.20) 
     
Facility Factors     
US Census region 
of the CLC 
    
Northeast Ref Ref Ref Ref 
Midwest 0.98 (0.67-1.42) 0.97 (0.79-1.20) 1.09 (0.79-1.49) 0.89 (0.67-1.16) 
South 1.15 (0.77-1.73) 1.16 (0.96-1.41) 1.18 (0.88-1.56) 1.09 (0.86-1.38) 
West 1.50 (0.96-2.35) 1.20 (0.89-1.63) 1.33 (0.92-1.93) 1.15 (0.81-1.63) 
Urban Influence 
Code for the CLC 
    
Large metro Ref Ref Ref Ref 
Small metro 1.03 (0.80-1.33) 0.90 (0.77-1.06) 0.89 (0.69-1.14) 0.90 (0.76-1.07) 
Micropolitan 1.44 (0.90-2.30) 1.15 (0.88-1.50) 1.19 (0.73-1.96) 1.07 (0.83-1.37) 
Noncore rural 0.79 (0.42-1.50) 0.79 (0.59-1.05) 0.84 (0.58-1.21) 0.75 (0.54-1.02) 
Complexity Level 
of the parent 
station 
    
1a (Highest) Ref Ref Ref Ref 
1b   0.87 (0.53-1.44) 0.84 (0.65-1.09) 0.70 (0.48-1.00) 0.99 (0.76-1.30) 
1c 0.82 (0.61-1.11) 0.82 (0.67-1.01) 0.75 (0.53-1.05) 0.89 (0.71-1.12) 
2 0.97 (0.71-1.33) 1.01 (0.81-1.26) 1.02 (0.70-1.47) 0.95 (0.71-1.27) 
3 (Least 
Complex) 
0.72 (0.50-1.03) 0.97 (0.77-1.23) 0.89 (0.63-1.25) 1.02 (0.76-1.39) 
Bed Size of CLC     
>120 beds Ref Ref Ref Ref 
60-120 beds 0.80 (0.57-1.10) 0.90 (0.73-1.11) 0.94 (0.68-1.29) 0.88 (0.68-1.15) 
<60 beds 0.66 (0.48-0.91)** 0.85 (0.70-1.03) 0.91 (0.69-1.21) 0.81 (0.64-1.03) 
MD turnover rate     
Quartile 1 Ref Ref Ref Ref 
Quartile 2 0.98 (0.73-1.32) 1.00 (0.83-1.20) 1.11 (0.89-1.40) 0.91 (0.73-1.14) 
Quartile 3 1.03 (0.77-1.39) 1.11 (0.92-1.35) 1.13 (0.84-1.50) 1.07 (0.88-1.32) 
Quartile 4 0.92 (0.73-1.16) 1.05  (0.89-1.25) 1.20 (0.91-1.57) 0.98 (0.79-1.22) 
Nurse turnover 
rate 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 0.94 (0.70-1.27) 0.86 (0.71-1.04) 0.84 (0.62-1.14) 0.85 (0.67-1.09) 
Quartile 3 0.93 (0.69-1.25) 0.85 (0.69-1.05) 0.84 (0.60-1.17) 0.86 (0.68-1.09) 
Quartile 4 0.90 (0.67-1.21) 0.80 (0.65-0.98)* 0.82 (0.60-1.14) 0.78 (0.61-1.00) 
Pharmacist 
turnover rate 
    
Quartile 1 Ref Ref Ref Ref 
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Quartile 2 0.95 (0.74-1.21) 0.98 (0.81-1.18) 1.13 (0.88-1.45) 0.92 (0.70-1.19) 
Quartile 3 1.14 (0.91-1.42) 1.04 (0.88-1.24) 1.34 (1.03-1.75)* 0.90 (0.71-1.15) 
Quartile 4 1.00 (0.77-1.30) 1.01 (0.84-1.22) 1.12 (0.86-1.47) 0.99 (0.72-1.28) 
Practical nurse 
turnover 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 1.27 (0.94-1.73) 1.19 (0.98-1.43) 1.41 (1.07-1.87)* 1.02 (0.80-1.31) 
Quartile 3 1.19 (0.89-1.58) 1.28 (1.08-1.51)** 1.44 (1.10-1.88)** 1.09 (0.89-1.35) 
Quartile 4 1.38 (0.99-1.94) 1.18 (0.96-1.46) 1.19 (0.86-1.67) 1.18 (0.94-1.47) 
Psychology 
Turnover 
    
Quartile 1 Ref Ref Ref Ref 
Quartile 2 1.23 (0.95-1.58) 1.15 (0.97-1.37) 1.50 (1.14-1.97)** 0.93 (0.76-1.15) 
Quartile 3 0.89 (0.71-1.12) 0.95 (0.79-1.15) 1.22 (0.94-1.60) 0.78 (0.63-0.98)* 
Quartile 4 0.94 (0.73-1.20) 0.84 (0.69-1.02) 1.03 (0.78-1.36) 0.69 (0.53-0.89)** 
Medications 
prescribed (which 
may impact 
Aspirin Rx) 
    
Anti-platelet 
agents 
0.84 (0.70-1.00) 0.93 (0.82-1.07) 0.90 (0.72-1.12) 1.00 (0.85-1.18) 
Anti-
thrombotic 
agents 
1.19 (1.02-1.39)* 1.13 (1.00-1.29) 1.17 (0.98-1.39) 1.10 (0.95-1.28) 
H2RAs 0.97 (0.76-1.22) 0.94 (0.80-1.10) 0.91 (0.72-1.15) 1.00 (0.79-1.28) 
PPIs 1.08 (0.95-1.23) 0.99 (0.89-1.09) 1.04 (0.91-1.20) 0.97 (0.85-1.12) 
NSAIDs 1.10 (0.83-1.44) 1.04 (0.83-1.29) 1.03 (0.70-1.52) 1.06 (0.80-1.42) 
*p<0.05, **p<0.01, ¥ indicates the variable was imputed   
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4.0 Discussion 
Continuation of aspirin for secondary prevention at end-of-life is controversial, given 
increased risks and unclear evidence about continued benefits; yet little is known about real-world 
patterns of aspirin use in patients near the end of life. In this large, national study of Veteran with 
LLE/AD who were admitted to VA CLCs over FY2009-2015, we found considerable variation in 
both aspirin use at CLC admission and subsequent aspirin discontinuation in those taking aspirin 
at admission. Specifically, only 48% used aspirin at admission, and one-third of initial users 
discontinued aspirin by day 91 of the CLC stay. We identified a number of resident and facility 
factors significantly associated with both aspirin use at admission and subsequent aspirin 
discontinuation. The factors most strongly associated with increased odds of aspirin use at CLC 
admission included a diagnosis of congestive heart failure, an MI in the year prior to admission, 
and concomitant anti-platelet therapy. In addition, individuals with limited prognosis or hospice 
use documented at admission had both greatly reduced odds of aspirin use and greatly increased 
hazard of subsequent discontinuation of aspirin. Finally, a number of individual markers of poor 
prognosis also predicted increased hazard of aspirin discontinuation after admission. 
Current treatment guidelines recommend aspirin for secondary prevention indefinitely and 
do not address whether aspirin should be discontinued in the context of limited life expectancy, 
due to a lack of evidence on the risks and benefits of continuing aspirin in patients near the EOL. 
Therefore, it is difficult to judge whether or not the rate of receipt and discontinuation of aspirin 
observed in VA CLCs is reflective of “good” or “bad” care. The almost 50% split use of aspirin at 
CLC admission in this sample is not surprising, given this ambiguity. Our results highlight the 
need for future comparative effectiveness and safety studies of aspirin withdrawal in this 
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population. As randomized controlled trials of medication withdrawal in patients nearing the end 
of life face considerable feasibility barriers, further research using epidemiologic designs and 
existing healthcare data amongst large cohorts of older adults at EOL will be integral in our 
understanding of the risks and benefits of aspirin discontinuation. The data available within the 
VHA CLCs, which includes utilization data from both the VHA and Medicare, as well as a rich 
supply of clinical and facility level characteristics, would be an excellent resource for conducting 
such studies and allow for control of a large number of potential factors that could confound the 
relationship between aspirin discontinuation and outcomes. In recent commentary by Hilmer and 
Gnjidic, literature supports the deprescribing of medication such as central-nervous system acting 
medications to reduce outcomes such as falls, but falls short regarding literature pertaining to 
deprescribing in the setting of polypharmacy – and how this impacts the patient in terms of 
successful aging and quality of life. They go on to also discuss the critical need to move beyond 
the crutch of a clinical trial for these outcomes, demanding further research by observational 
studies, something which can certainly be conducted in the VHA setting.83 In addition, the 
variation in aspirin discontinuation we observed across this population in the VHA CLC would be 
a strength for future epidemiologic studies, in that this variation can be harnessed to examine the 
effect of aspirin discontinuation on health outcomes in patients with LLE and/or AD. 
We identified a number of factors in this study that were statistically significantly 
associated with higher and lower odds of aspirin receipt and hazard of aspirin discontinuation. 
Although it important to consider the exploratory nature of this study, our results generally lend to 
support to our conceptual model, which proposed that cardiovascular risk factors may encourage 
continuation of aspirin in this population, while markers of poor prognosis – and particularly 
explicit documentation of a new CLC resident as having limited prognosis or as a hospice patient 
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– may discourage its continuation. Our model was also supported in that several socio-
demographic, environment of care factors, and facility characteristics were significantly associated 
with aspirin use and discontinuation. By including so many variables in these models, some of 
these variables will be statistically significant by chance alone; and, given the large sample, we 
were highly powered to see small differences between those who did and did not receive aspirin 
and those who did and did not discontinue aspirin. Notably, those factors which were more strongly 
associated with greater odds of aspirin receipt at admission and pose clinical implications included 
having had a recent myocardial infarction, concomitant treatment with antiplatelets (which is 
common pharmacological management post-MI), hypertension, and hypertension. We also found 
an increased odds of aspirin receipt associated with each class of medications we assessed, which 
may be reflective of a propensity toward polypharmacy. In addition to those with documentation 
of limited prognosis or hospice use at admission, receipt of aspirin was also markedly lower 
amongst females, those with a prior venous thromboembolism, those with cancer, those with 
greater ADL dependence, and patients of Hispanic ethnicity. With the exception of female sex, 
many of these same factors were also associated with aspirin discontinuation after admission, 
along with additional markers of poor prognosis.  
In the absence of evidence regarding outcomes of aspirin discontinuation in older adults 
with LLE, managing aspirin will remain difficult in this population. Currently, it is unclear if older 
adults at EOL would benefit from discontinuation of aspirin for secondary prevention. The 
variability of aspirin prescribing for secondary prevention we observed in this study is directly at 
odds with treatment guidelines which strongly recommend initiating and indefinitely continuing 
use of aspirin, but in line with the predominant model that is used in geriatrics and palliative care 
when considering candidate medications for deprescribing.29 Importantly, factors which predict 
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poor prognosis, such as cancer, high dependency on ADLs, and renal failure were associated with 
lower odds of aspirin receipt and higher hazards of aspirin discontinuation. This may indicate that 
prescribers are considering these factors heavily when considering the role of aspirin in these 
patients. While guidelines rarely recommend against the use of aspirin in this population, it is 
important to consider factors that increase one’s risk of bleeding, such as being of older age, renal 
insufficiency, and concomitant use of other medications such as NSAIDs, anti-platelets and anti-
thrombotic agents. The risk of major bleeding events is almost 3-fold higher in those on aspirin 
for secondary prevention versus placebo, while aspirin use reduces the risk of stroke and other 
cardiovascular disease by about 20%.14 Without consensus amongst the geriatric and palliative 
care experts, the continuation of aspirin should be weighed against the risk of bleeding – of which 
gastrointestinal bleedings are significantly higher in older adults, and such bleeds are often more 
fatal and disabling in this population versus younger adults. The risk of a potential prothrombotic 
window shortly after aspirin discontinuation should be discussed with the patient as well. In the 
absence of withdrawal studies, this must be an individualized approach, which includes 
incorporating the patient and their caregivers’ goals of care, and should be a shared decision 
making process.  
 Our results are generally consistent with a recent cross-sectional study of US adults with 
CAD surveyed by the 2015 Behavioral Risk Factor Surveillance System. Aspirin use was 
significantly associated with male sex, hypertension, diabetes, and “less than excellent general 
health” as reported by the patient. Lower reporting of aspirin use was associated with female sex, 
having less than a high school education, and self-reporting “excellent” health.3 “Excellent-health” 
may be an indicator for lower rates of chronic comorbidities or concomitant medications, though 
it is unclear from this survey if this is true. Additionally, consistent with other studies looking at 
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chronic CVD medications in older adults, prescribing of aspirin was less likely amongst females.44 
However, older age was associated with higher odds of aspirin receipt and lower hazards of aspirin 
discontinuation in our study, contrary to our hypothesis that older age would predict lower odds 
of aspirin receipt and higher hazards of aspirin discontinuation. Regional differences in prescribing 
were also seen, though only in the West compared to the Northeast.44 High odds of prescribing 
chronic CVD medication for secondary prevention was seen amongst those with CHF, and 
hypertension; lower odds of prescribing these medications occurred in those with atrial fibrillation, 
and in those with more extensive dependence in ADLs.44, 45 As there are few studies which assess 
discontinuation of cardiovascular medications and factors predicting discontinuation in patients 
near the EOL, and none focusing on aspirin, there is little prior evidence to which we can compare 
our findings regarding predictors of discontinuation specifically. 
 
4.1 Strengths 
To our knowledge, this is the first national study examining prevalence and predictors of aspirin 
use and discontinuation in an end-of-life nursing home population. In addition, the use of BCMA 
data increases the novelty of this study. By using this data set, we can capture the total daily dose 
of all medications. In this study, it was highly important to be able to find those who were on a 
specific daily dose which is recommended for secondary prevention of CVD. This data is also 
important for determining exactly when a medication is initiated, discontinued, and re-started. For 
this study, it was imperative that proof of administration was available to determine if a patient 
met criteria for deprescribing, as well. Because most claims data only allow you to observe if a 
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patient was prescribed a medication every 30-90 days, typically a gap of at least 30 days is required 
to determine if a patient was potentially deprescribed on that medication. In this case, using BCMA 
data which provides information on daily administration of aspirin, we could theoretically rely on 
a shorter gap (e.g., 14 days) to confidently conclude discontinuation. This short gap period for 
discontinuation may reduce selection bias due to excluding or censoring potentially sicker patients 
who do not have this follow-up time available. Further, sensitivity analysis was performed using 
the traditional 30 day window; however in this case, we have much greater certainty than in studies 
relying on outpatient prescription drug claims or dispensing records that the patient truly not ingest 
the medication during those 30 days. This is especially important with regard to studying aspirin 
use and discontinuation, given that aspirin can be obtained over-the-counter and may not be 
reliably captured in claims or outpatient pharmacy dispensing records.  
Another strength of this study was the incorporation of many chronic medications and 
chronic diseases which are either associated with aspirin use or CVD. This allowed us to explore 
more completely the predictors of receipt of aspirin and discontinuation of aspirin for secondary 
prevention in this population. Specifically, the inclusion of MDS variables allows us to evaluate 
more clinical prognostic factors than prior studies have included.44-46 Additionally, using 
competing risk survival analysis is a major strength of this study, as it does not bias upward the 
cumulative incidence of deprescribing.  
4.2 Limitations 
A key limitation of our study is the unknown generalizability of our findings in non-
Veteran end-of-life populations residing in non-VHA nursing homes (who, in contract to this 
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study’s sample, are typically majority female), as well as to individuals near the EOL who remain 
in the community and are managed in outpatient settings. However, given that VHA and non-VHA 
guidelines do not differ with regard to recommendations for aspirin use in end-of-life populations, 
it is likely that similar care patterns would exist outside of VHA CLCs.  
Another limitation of this study was our assumption of proportional hazards; i.e., that the 
effect of a given predictor variable on hazard of aspirin discontinuation does not vary over time. 
In cases where this assumption is violated and not addressed by altering the modeling approach, 
the reported hazard ratios must be interpreted as the average hazard over the 91 days of inclusion 
in the study, as opposed to an instantaneous hazard of deprescribing. There are several ways to 
address violations of the proportional hazards assumption, although all have difficulties. One 
approach is to split the model at different time periods and acquire different hazards of the event 
for each time period chosen. However, this method can introduce selection bias.84 Alternatively, 
interaction terms can be introduced to the model by creating new variables that interact time with 
each variable that violates the assumption. However, this greatly increases the complexity of the 
modeling and can introduce variables which have SDHRs which are inherently difficult to 
interpret. In the discontinuation analysis for this study, we did test for violations of the proportional 
hazards assumption by interacting each variable in the bivariable competing risk models with 
follow-up time measured in days. In interpreting the p-values on these interaction terms to identify 
variables with significant interactions with time, we used a Bonferroni correction to account for 
the fact that with over 50 predictor variables (p<0.00098 indicates significant difference using a 
model with 51 total variables), some of these variables would violate the assumption by chance 
alone.85 Using the Bonferroni correction, the following variables violated the assumption: the 
indicator for limited prognosis and hospice, leaving food uneaten, and dependency on ADLs. Thus, 
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for those variables, the reported SDHR must be interpreted as the average hazard of 
discontinuation over the 91 days of inclusion in the study, rather than the instantaneous hazard of 
deprescribing. Finally, a third limitation of our approach is the potential for measurement error in 
covariates that are defined based on past healthcare utilization (e.g., comorbidities). In cases where 
a resident had non-VHA health insurance other than Medicare fee-for-service, these conditions 
may be under-captured. However, the concomitant use of MDS assessments along with past 
healthcare utilization records to define most of the comorbidities likely minimized these errors. 
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5.0 Conclusion 
Aspirin use for secondary prevention in Veteran nursing home residents with LLE and/or 
AD varied across patients, with just under 50% taking aspirin at CLC admission and only one-
third subsequently having aspirin discontinued in the first 91 days of the CLC stay. Further 
qualitative studies may be useful in evaluating the decision-making process of continuing and 
discontinuing aspirin in those with LLE in this population. Next steps may include assessing 
effects of continuing versus discontinuing aspirin on negative cardiovascular outcomes (non-fatal 
MI, stroke, TIA, death due to cardiovascular disease, all-cause mortality) and negative bleeding 
outcomes (hospitalization due to bleeding events, death due to bleeding event, hemorrhagic stroke, 
major extracranial bleeding) among users of aspirin for secondary CVD prevention, which may 
better inform prescribers about the risk of discontinuing aspirin in this vulnerable population in 
the setting of lack of expert consensus and guideline recommendations.  
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